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ABSTRACT
Metabolic Plasticity in the Cellular Stress Response
by
Ying Li
Changes to the metabolism of the cardiomyocyte are driven by complex signaling
pathways in order to adjust to stress. For instance, HIF-1α is classically known to
upregulate glycolytic metabolism to compensate for oxygen deficiency. Other important
effects upon glucose metabolism, which we investigate here more extensively, were
also observed. Hearts derived from mice with the cardiac-restricted expression of a
stabilized form of HIF-1α are remarkably ischemia stress-tolerant. Here, stable isotoperesolved metabolomic analyses were utilized to investigate glucose cardiometabolism
remodeling by HIF-1α during ischemia. We found that 13C-lactate accumulation was
significantly elevated in HIF-1α expressing hearts while paradoxically glycogen was
maintained to a remarkable extent during an ischemic time course. These findings
suggested an unexpected source of glucose in HIF-1α hearts during global ischemia.
Accordingly, the presence of gluconeogenesis in hearts was evaluated. Indeed,
gluconeogenic intermediates (i.e. m+3) including glucose-6-phosphate [m+3], fructose6-phosphate [m+3], and fructose 1,6-bisphosphate [m+3] were observed at significantly
elevated levels in the ischemic HIF-1α heart. Collectively, these data establish the
surprising finding that HIF-1α supports active gluconeogenesis in the heart during
ischemia.
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As less is known regarding the effects of CTRP3 we first tested whether CTRP3
overexpression would protect the ischemic heart. Our data indicate that CTRP3 failed to
confer ischemic tolerance in heart ex vivo. However, we were able to show that CTRP3
protected the liver from lipid-induced stress and prevented hepatic lipid accumulation.
To further investigate the mechanisms of hepatic protective effect mediated by CTRP3,
we identified the receptor and established that CTRP3 increases oxygen consumption
in response to lipid overloaded.
In summary, these data indicate that targeted metabolic rearrangements within
cardiomyocyte/hepatocyte holds promise for the alleviation of common pathological
conditions.
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CHAPTER 1
INTRODUCTION
Metabolic disturbances have been commonly characterized in diverse diseases
such as obesity, diabetes, ischemic heart disease, and nonalcoholic fatty liver disease
(NAFLD) (Ahmed et al. 2012; Ballestri et al. 2016). The mortality rates of heart disease
and stroke remain the top and third leading causes of death, respectively, in the United
States over the last four decades (1975-2015).
During Myocardial infarction blood flow to the heart is stopped whereas during a
stroke blood flow to the brain is inhibited. In both cases the resulting hypoxia is a major
component involved in the severity of these diseases. Thus, identifying the cellular
response to the low oxygen levels of great clinical importance.
HIF-1α
The transcription factor hypoxia inducible factor-1 (HIF-1) functions as a
principal regulator of the cellular response to hypoxia. HIF-1 is a heterodimeric complex
comprised of O2-labile α subunit (120 kDa) and the constitutively expressed β subunit
(91-94 kDa) (Wang and Semenza 1995; Wang et al. 1995). When oxygen is present,
prolyl hydroxylase (PHDs) hydroxylate at the oxygen-dependent degradation (ODD)
domain of HIF-1α at proline 402 and proline 564, which targets the protein for rapid
degradation. Insufficient O2 tension promotes HIF-1α stability by inhibiting the activity of
PHDs (Salceda and Caro 1997; Huang et al. 1998; Maxwell et al. 1999; Ivan et al. 2001;
Jaakkola et al. 2001). In addition, during hypoxia, HIF-1α transcription is stimulated.
Briefly, when oxygen is present factor inhibiting HIF-1 (FIH-1) hydroxylates asparagine
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803 at the c-terminal transactivation domains (TAD-C) of HIF-1α, which blocks HIF-1α
from interacting with the coactivators CREB binding protein (CBP) and 300-kilodalton
coactivator protein (p300) for its transcriptional activity (Mahon et al. 2001; Dames et al.
2002; Lando, Peet, Gorman, et al. 2002; Lando, Peet, Whelan, et al. 2002; Elkins et al.
2003; Freedman et al. 2002; Hewitson et al. 2002). However, during hypoxia HIF-1α
accumulation facilitates the formation of functional heterodimeric transcription factor
HIF-1 with the coactivators and binds to the core DNA recognition sequence 5′-RCGTG3′ within hypoxia response elements (HRE), and activities full transcriptional activity
(Forsythe et al. 1996; Semenza et al. 1996; Wang et al. 1995). Thus, the stability and
activity of HIF-1α are closely regulated by oxygen availability. HIF-1α, in turn, initiates
regulation of a wide variety of downstream target genes that mediate the cellular
adaptation to hypoxia.
The role of HIF-1α was first established in erythropoiesis (Semenza and Wang,
1992; Wang and Semenza, 1996), and later in angiogenesis (Liu et al. 1995; Forsythe
et al. 1996; Gerber et al. 1997), metabolism (Iyer et al. 1998; Seagroves et al. 2001),
cell proliferation and apoptosis (Carmeliet et al. 1998). In many pathological settings,
the HIF-1 signaling pathway is activated in order to cope with hypoxic stress. For
instance, HIF-1α is essential factor for inflammatory pathogenesis mediated by the
neutrophils and macrophages (Cramer et al. 2003). It has recently been revealed that
inflammatory genes are promoted by HIF-1α-mediated metabolic reprogramming by in
macrophages, dendritic cells (DCs), T-cells, and neutrophils (Corcoran and O’Neill
2016). HIF-1α is also associated frequently with cancer as a result of intratumoral
hypoxia and genetic alterations (Semenza 2003). Evidence is observed that HIF-1α is
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overexpressed in solid tumors (Semenza 2003; Bertout et al. 2008). Stabilized HIF-1α
has also been described to induce the expression of vascular endothelial growth factor
(VEGF) in atherosclerotic lesions (Vink et al. 2007).
HIF-1α has been shown to confer cellular protection in ischemic heart. For
example, In the setting of ischemic preconditioning (IPC), short-episodes of ischemia
and reperfusion confer cardioprotection during subsequent prolonged injury of ischemiareperfusion (Murry et al. 1986; Rosenberg et al. 2018). The acute cardioprotection was
lost in HIF-1α heterozygous-null or knockout mice, indicating that HIF-1α activity is
essential for the potential benefits from IPC stimulus (Cai et al. 2008; Sarkar et al.
2012). Other downstream targets of HIF-1α such as nitric oxide synthase (NOS),
vascular endothelial growth factor (VEGF), and heme oxygenase-1 (HO-1), have been
shown to promote tolerance to ischemic stress in mice hearts or isolated
cardiomyocytes (Guo et al. 1999; Jung et al. 2000; Ockaili 2005; Li et al. 2007).
In recent studies, we have utilized a transgenic adult mouse with a cardiacspecific, oxygen-stabilized, and doxycycline(Dox)-off HIF-1α expression (HIF-1α-PPN)
to probe the roles of HIF-1α in ischemic tolerance. The results show that HIF-1α elicits
robust protection in the mouse hearts subjected to the global ischemia, ex vivo (J. Wu et
al. 2013). These studies also revealed evidence that glucose metabolism was
remodeled in the HIF-1α hearts (J. Wu et al. 2013). We have previously identified
several HIF-1α-induced metabolic pathways contributing to the ischemic
cardioprotection.(J. Wu et al. 2015) In HIF-1α-expressing hearts, the purine nucleotide
cycle (PNC) was found to be upregulated. The PNC preserves the adenylate energy
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charge and protects myocardia from toxic accumulation of adenosine during ischemia.
The nucleotide salvage enzyme hypoxanthine phosphoribosyl transferase (HPRT) was
also found to be induced by HIF-1α. HPRT recycles the nucleotide degradation product
hypoxanthine and prevents potential damage from hydrogen peroxide (H2O2) generated
by xanthine oxidase during reperfusion of ischemic heart (J. Wu et al. 2015).
CTRP3
CTRP3 also functions as a metabolic regulator and has versatile effects in
multi-type tissues (reviewed in chapter 3) (Li et al. 2017). C1q TNF-related protein-3
(CTRP3) is a distinctive member of highly conserved CTRP family that comprises a
suite of paralogs of adiponectin (Wong et al. 2004). Several reports have suggested that
CTRP3 contributes to cardio-metabolic regulation in cardiovascular diseases. For
example, myocardial infarction (MI) was shown to lead to lower CTRP3 tissue
expressions and plasma CTRP3 level (Yi et al. 2012; D. Wu et al. 2015). Infusions of
globular CTRP3 or CTRP3 adenovirus improved functional recovery of the left ventricle
and prevented pathological remodeling of fibrosis following MI injury in myocardia (Yi et
al. 2012; D. Wu et al. 2015). The anti-fibrotic effect of CTRP3 was induced by inhibitions
of phosphorylation of Smad-3 in post-infarct myocardia (D. Wu et al. 2015). The vessels
formation in the infarcted border zone has been shown to be promoted through CTRP3induced phosphorylations of Akt, HIF-1α, and VEGF in the myocardium (Yi et al. 2012).
Finally recent studies showed that the treatment of CTRP3 ameliorates mitochondrial
dysfunction after hypoxia-reoxygenation injury in neonatal cardiomyocytes (Zhang et al.
2017).
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Taken together, these data suggested the potential of CTRP3 as a prospective
modulator for ischemic heart disease. We therefore sought to probe the role of CTRP3
in cardioprotection. A transgenic mouse model of CTRP3 overexpression was used in
this study. WT and CTRP3 overexpressing hearts were retrograde perfused via the
aorta and subjected to 30 mins of ischemia followed by 30 mins of reperfusion, ex vivo.
Subsequent recovery of function and tissue viability were assessed upon reperfusion of
heart. Our results showed that recovery of left ventricular developed pressure (LVDP) in
CTRP3 overexpressing hearts after ischemia, was not significantly better (22% vs 39%,
P>0.05). (Figure 1.1) In addition, there are no significant differences in tissue viability
after reperfusion between WT and CTRP3 overexpressing hearts. (Figure 1.2) These
results indicated that CTRP3 does not confer specific cardioprotection at least in this
model of hypoxic injury.

13

Figure 1.1: Cardiac Response to Ischemic Stress. A. condensed pressure tracings were shown
from Langendorff-perfused hearts derived from wildtype (WT) and CTRP3 overexpressing
(CTRP3) mice. Following 20 mins of pre-ischemic perfusion, hearts were subjected to 30 mins
of ischemia and subsequently to 30 mins of reperfusion and left ventricular developed pressure
(LVDP) was measured. B. quantification of the recovery of LVDP after ischemia, expressed as a
percent of pre-ischemic LVDP is shown. P > 0.05 vs. WT; n = 3-5 hearts.
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Figure 1.2: Myocardial Ischemic Injury Indicated by Triphenyltetrazolium Chloride (TTC)
Staining. A. Langendorff-perfused hearts derived from wildtype (WT) and CTRP3
overexpressing (CTRP3) mice were collected following 30 mins of reperfusion after 30 mins of
ischemia. Viable (red) and inviable tissue (pale) were shown in sectioned hearts. B.
quantification of viable tissue, expressed as a percent of each heart tissue. P > 0.05 vs. WT; n =
3-5 hearts.

By comparison, CTRP3 appears to protect the liver from lipid-induced stress
and regulate hepatic metabolism. For example, we initially established evidence that
CTRP3 maintains glucose homeostasis by suppression of hepatic gluconeogenesis via
protein kinase B (Peterson et al. 2010). Insulin resistance and dyslipidemia have
emerged as the most predominant features and pathological basis of NAFLD. NAFLD
refers to a spectrum of pathological phenotypes comprising simple steatosis,
nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. Accumulation of
hepatocellular lipid metabolites is recognized as the first “hit” of complex mechanisms of
NAFLD to induce the ultimate liver injury (Perla et al. 2017). The net lipid flux is
enhanced and causes dysregulation of lipid and lipoprotein metabolism, eventually
developing into the overload of lipid in hepatocytes. The excessive lipid retention leads
to insulin resistance via the stimulation of glucose secretion and inhibition of the
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phosphorylation of the insulin receptor substrate (IRS)-1/ IRS-2 in liver (Perla et al.
2017).
Interestingly, we have found that CTRP3 overexpressing efficiently limits the
development of high fat diet-induced hepatic steatosis and insulin resistance 48. This
effect is associated with the suppression of hepatic triglyceride synthesis enzymes
(Peterson et al. 2013). Consistent with in vivo data, rCTRP3 treatment reduced fatty
acid synthesis and lipid accumulation in rat H4IIE hepatocytes (Peterson et al. 2013). In
CTRP3 knockout mice, however, hepatic triglycerides were elevated after high fat diet
fed.(Wolf et al. 2016) In contrast, these CTRP3-induced metabolic changes have not
been found in mice fed with a low fat diet (Peterson et al. 2013; Wolf et al. 2016).
Collectively, although these data indicate that CTRP3 regulate hepatic lipid metabolism
in response to high fat diet-induced stress, the mechanisms deserve to be further
investigated. Thus it needs to be clarified whether CTRP3 acts directly or is mediated by
potential receptors in hepatocytes.
Overall Hypothesis and Specific Aims
The overall goal of this dissertation was to investigate mechanisms to
manipulate the cellular response to stress to prevent/treat disease. Based on the
discussion above, this study aimed to identify unique metabolic mechanisms induced by
HIF-1α and CTRP3 that respond to stress conditions. Aim 1) was to determine the
cardiometabolic flux, particularly as it relates to glucose metabolism and to further
elucidate the mechanisms responsible for HIF-1α’s ischemic protection. In chapter 2 we
describe how we used metabolomics analysis to show that glucose metabolism was
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different in the HIF-1α-expressing heart during ischemia. Specifically, we observed
convincing evidence that HIF-1α induces gluconeogenic pathway. These studies have
identified a number of potential mechanisms to explain the cardioprotective effects of
HIF-1α. Aim 2) was to investigate the heart and hepatic protective effects of CTRP3
based upon remodeling of lipid metabolism to high fat diet-induced stress. In chapter 3
we review CTRP3 function and regulation. In chapter 4 we demonstrate that CTRP3
promotes fatty acid utilization following lipid overload in vitro and identified a putative
receptor for CTRP3.
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CHAPTER 2
HIF-1α IN HEART: EVIDENCE OF GLUCONEOGENESIS IN MYOCARDIUM
DURING ISCHEMIA
Li Y 1, Warmoes MO 2, Lin PH 2, Peterson JM 1,3, Bolton NW 1 and Wright GL 1.
1

Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State
University, Johnson City, TN 2 Center for Environmental and Systems Biochemistry, Markey
Cancer Center, University of Kentucky, Lexington, KY
3
Department of Health Sciences, College of Public Health, East Tennessee State University,
Johnson City, TN

ABSTRACT
Hypoxia inducible-1α (HIF-1α) is a transcription factor that directs multiple cellular
changes to adapt to low oxygen conditions. Previously we have shown that hearts derived
from mice with the cardiac-restricted overexpression of HIF-1α are remarkably ischemia
stress-tolerant (4). The current studies are designed to further probe the metabolic
rearrangements directed by HIF-1α, particularly as they relate to glucose metabolism. U13

C6 glucose was loaded into Wild-type (WT) and HIF-1α expressing hearts for 30 mins,

ex vivo. Subsequently the hearts were subjected to global zero-flow ischemia (0, 5, 10,
15, and 30 mins) and flash frozen. Polar metabolites were subsequently extracted. In
parallel, myocardial protein was collected for western blot analysis. The incorporation of
13

C in the metabolome reservoir of the heart was determined by Nuclear Magnetic

Resonance (NMR) spectroscopy and Ion-Cyclotron Resonance coupled Mass
Spectrometry (ICR-MS). Indicating enhanced glycolytic flux,
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C-lactate accumulated in

HIF-1α hearts and WT hearts as ischemia progressed but was significantly elevated in
the HIF-1α hearts. Glucose reserves (i.e. glycogen) are maintained to a remarkable extent
at 5, 10 and 30 mins of ischemia in HIF-1α hearts while, in stark contrast, glycogen is
largely depleted after 5 mins of ischemia in WT hearts.
18

13

C-Glucose incorporation into

glycogen is maintained at pre-ischemic levels in HIF-1α hearts for up to 30 mins of
ischemia while becoming undetectable in WT hearts. These findings suggested an
unexpected source of glucose in the ischemic HIF-1α heart. Accordingly, the presence
of gluconeogenesis in hearts was evaluated. Indeed, IC-MS detected gluconeogenic
intermediates (i.e. m+3) including glucose-6-phosphate [m+3], fructose-6-phosphate
[m+3], and fructose-1-6-bisphosphate [m+3] at statistically elevated levels in HIF-1α
hearts during ischemia. Taken together, these data establish the surprising finding that
HIF-1α supports active gluconeogenesis in the heart during ischemia.
INTRODUCTION
Hypoxia inducible factor-1α (HIF-1α) is “master regulatory” transcription factor
that governs the expression of over 120 genes, including those functioning metabolic
adaptation, angiogenesis, tumorigenesis, inflammation, and apoptosis (1). HIF-1α is
functional as a heterodimer composed of the oxygen-regulated α-subunit and a
constitutively expressed β-subunit (also known as ARNT). The heterodimers bind to
hypoxia response elements (HREs) to regulate nuclear transcriptional activity of target
genes.
The stability of HIF-1α is regulated by the proline hydroxylase domain-containing
proteins (PHD) which serve as oxygen sensors. HIF-1α is subjected to hydroxylation
which leads to its ubiquitination by the von Hipple-Lindau protein (pVHL) for consequent
proteasomal degradation (2). The activity of the dioxygenase PHDs diminishes with
oxygen shortage and the reduced post-translation hydroxylation of HIF-1α results in its
stabilization. Hypoxia also lowers the activity of the factor inhibiting HIF (FIH), an
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asparaginyl hydroxylase which inhibits HIF-1α transcriptional activity by preventing
recruitment of co-activator (3). In these studies, we use a transgenic mouse model
containing HIF-1α cDNA with alanine substitutions at Pro402, Pro564, and Asn803 as
described in our previous studies (4, 5). This HIF-1α construct displays full transcriptional
activity and the protein is stabilized under normoxic conditions. Moreover, HIF-1α protein
(termed as “HIF-1α-PPN) is yoked to a TET-off γ-myosin promoter effecting
cardiomyocyte-specific expression controlled by a doxycycline-diet.
Hypoxia is fundamental stimuli that initiates a number of cellular adaptive
responses in the myocyte. In heart, it has been widely known that flux through glycolysis
is stimulated and lactate production is preferred while fatty acid oxidation is actively
suppressed during low oxygen availability. Glucose transportation is also increased by
HIF-1α through an upregulation of GLUT-1 (6). During chronic hypoxia, reduced
mitochondrial metabolism is a strategy to maintain redox homeostasis and cell survival
against excessive levels of reactive oxygen species (ROS). For example, pyruvate
dehydrogenase kinase 1 (PDK1) prevents the conversion from pyruvate to acetyl-CoA
through the tricarboxylic acid (TCA) cycle, which allows the shift from oxidative to
glycolytic metabolism. The gene encoding PDK1 protein is directly activated by HIF-1α,
thus shifting glucose from the oxidative to the fermentative pathways (7, 8).
In a transgenic murine model where HIF-1α is stably expressed in heart, we
previously demonstrated remarkable protection against ischemia-reperfusion injury, ex
vivo, and anaerobic fumarate respiration which preserves mitochondrial polarization
during anoxia (4). Further investigation revealed that AMP deaminase (AMPD), the entry
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point of the purine nucleotide cycle (PNC), is upregulated by HIF-1α, which results in
inhibiting production of adenosine in myocardium during ischemia and favors production
of fumarate to support the above mentioned fumarate reductase activity (5). These results
indicated that HIF-1α regulates nucleotide metabolism as a compensatory response to
metabolic perturbations which provides fumarate and conserves the nucleotide pool
during hypoxia (5). Despite these recent advances in understanding the mechanisms of
cardioprotection induced by HIF-1α during ischemic stress, the role of remodeling of
glucose metabolism by HIF-1α remains unclear. These studies were undertaken to further
probe the cardio-specific role of HIF-1α in cardioprotection, especially as they are related
to glucose metabolism.
Metabolomics is a platform enabling the simultaneous qualitative measurement
of metabolites in biological samples. 1H NMR and MS techniques are two popular
analytical techniques applied to the analysis of the metabolic profile (9, 10). Here, a
metabolomics approach based on 1H NMR and MS was used to quantify metabolite levels
in heart during ischemia and to probe the underlying metabolic mechanisms of
cardioprotection elicited by HIF-1α. Studies were performed in perfused mouse hearts
that had undergone ischemia following the incorporation of Uniform-13C6-(U-13C6) glucose,
with subsequent determination of metabolites downstream in glucose metabolism.
EXPERIMENTAL PROCEDURES
Animals. Male B6C3F1 mice contain a doxycycline-restraining HIF-1α transgene
(HIF-1α-PPN) that has been described previously (4). These HIF-1α-PPN mice are fed
daily with a doxycycline-loaded diet (625 mg/kg, Harlan Research Laboratories, Madison,
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WI). HIF-1α specific stably expressing in mouse heart is elicited after 5-7 days following
switching to regular diet. All wildtype and HIF-1α-expressing mice were used for the study
at 3.5-4.5 months of age. Procedures on animal experiments were performed in
accordance with the regulations issued by the East Tennessee State University
Committee on Animal Care.
Langendorff perfusion. Hearts were retrograde perfused through the aorta using
methods described previously. 4 Krebs-Henseleit buffer containing (mM): 118.5 NaCl, 4.7
KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8 NaCHO3, 2.5 CaCl2, and 10.6 glucose (U-13C6-glucose,
Cambridge Isotope Laboratories, Inc. Andover, MA) that has been made and then
warmed at 37°C using refrigerated circulating bath (VWR, Radnor, PA) during perfusion.
The buffer was equilibrated with mix of 95% O2/5% CO2 for at least 20 mins. U-13C6glucose was infused of 30 mins. Then hearts are subjected to global ischemia for 0, 5,
10, 15 or 30 mins, respectively. Hearts were flash-frozen by clamping with a set of
Wollenberger tongs that were prechilling in liquid nitrogen, where upon the hearts were
ground into a fine powder using a mortar and pestle with liquid N2.
Preparation of sample. The frozen powdered heart samples were quenched in a
cold cocktail of CH3CN:ddH2O=2:1.5 (CH3CN: Sigma, St. Louis, MO) after which, polar
compounds were extracted according to the lab protocols from Resource Center for
Stable Isotope-Resolved Metabolomics (University of Kentucky, KY). Briefly, 1mL of
CHCl3 (Sigma, St. Louis, MO) was added to ensure the ratio in samples (CH3CN:ddH2O:
CHCl3=2:1.5:1), shaken vigorously and vortexed, then centrifuged at 3,500 g at 4°C for
20 mins. The polar fraction (upper layer) and protein (middle layer) were collected and
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lyophilized for further experiments. Levels of metabolites in hearts were determined by
NMR and ICR/MS Spectrometers (Resource Center for Stable Isotope-Resolved
Metabolomics, University of Kentucky, KY).
1D 1H and 1H{13C} HSQC NMR analyses. Polar extracts were reconstituted in
D2O (> 99.9%, Cambridge Isotope Laboratories, MA) containing 0.1 mM EDTA
(Ethylenediaminetetraacetic acid, Sigma Aldrich, St. Louis, MO) and 0.5 mM d6-2,2dimethyl-2-silapentane-5-sulfonate (DSS) (Cambridge Isotope Laboratories, Tewksbury,
MA) as internal standard were performed on a DD2 14.1 Tesla NMR spectrometer
(Agilent Technologies, CA) equipped with a 3 mm inverse triple resonance HCN
cryoprobe. 1D 1H spectra were acquired with standard PRESAT pulse sequence at 15°C.
A total of 16384 data points were acquired with 2 s acquisition time, 512 transients, 12
ppm spectral width, and 4 s recycle delay time during which water peak was irradiated by
soft pulse for suppression. The spectra were then linear predicted and zero filled to 128k
points and apodized with 1 Hz exponential line broadening. 1D HSQC spectra were
recorded with 13C adiabatic decoupling scheme for broad range decoupling during proton
acquisition time of 0.25 s. 1796 data points were collected each transient and a total of
1024 transients were acquired with 12 ppm spectral width. The HSQC spectra were zero
filling to 16k data points before Fourier transformation and then apodized with unshifted
Gaussian function and 4 Hz exponential line broadening. Metabolites were assigned by
comparison with in-house (11) and public NMR databases. Metabolite and their
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C

isotopomers were quantified using the MestReNova software (Mestrelab, Spain) by peak
deconvolution. The peak intensities of metabolites obtained were converted into nmoles
by calibration against the peak intensity of internal standard DSS (27.5 nmoles) at 0 ppm
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for 1H spectra and that of Lac-3 at 1.32 ppm (nmoles determined from 1D 1H spectra) for
HSQC spectra before normalization to the dry residue weight of each sample extracted.
Ion Chromatography-Mass Spectrometry (IC-MS) analyses. Unless stated
otherwise, ICMS analysis was performed as previously described (12, 13). In short, polar
extracts were reconstituted in 20 µL nanopure water of which 10 µL was injected for
analysis on a Dionex ICS-5000+ion chromatograph interfaced to an Orbitrap Fusion
Tribrid mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA). MS1 mass
spectra were acquired at a resolution setting of 500,000 (FWHM at m/z 200) and an m/z
range from 80 to 700. The chromatograph was outfitted with a Dionex IonPac AG11-HC4 µm guard and column (both 2 × 50 mm). MS1 peak areas for isotopologues were
integrated and exported to Excel via the Thermo TraceFinder (version 3.3) software
package. Peak areas were corrected for natural abundance as previously described (14).
Western Blotting. Protein samples were separated in Pierce Tris-HEPES-SDS
4–20% precast polyacrylamide gels (Thermo scientific). Proteins were transferred to
polyvinylidene difluoride membranes (BioRad, Richmond, CA) at 300 mA for 1.5 hours.
following transfer, Ponceau S (Sigma) staining was used to ensure complete transfer
and equal protein loading. Membranes were blocked in 5% nonfat dry milk in 1xTBS
with 0.1% Tween 20 (TBS-T) for 1 hour at room temperature. Phospho-glycogen
synthase (Ser641) expression was probed with a rabbit monoclonal primary antibody
(Cell signaling #3891) at 1:1,000 dilution in TBS-T. The membrane was incubated at
4°C overnight and washed for 10 mins x 3 times in TBS-T before incubation with goat
anti-rabbit horseradish peroxidase-conjugated (HRP) secondary antibody. Protein
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bands were detected using the Pierce supersignal chemiluminescence substrate
(Thermo scientific) in the G:Box fluorescence and chemiluminescence imaging system
(Syngene, Frederick, MD). Densitometry was performed using ImageJ (National
Institutes of Health, Bethesda, MD).
Statistical Analysis. Quantified metabolite levels (umol or nmol/g protein) from
each experiment were expressed as means±SEM. Independent replicates were
combined and analyzed with a two-way ANOVA followed by Bonferroni's (for
metabolomics data) or Sidak’s (for western blot data) multiple comparisons analysis.
Statistical analyses were performed in Graphpad Prism 6 (La Jolla, CA).
RESULTS
Enhanced glycolytic flux in HIF-1α-expressing heart in response to ischemia with
the unexpected failure to deplete glycogen levels.
HIF-1α expression was specifically induced in murine cardiomyocytes through
the removal of Doxy diet for 5-7 days prior to the experiment. Wild-type (WT) and HIF-1α
expressing hearts were perfused with 10.6 mM U-13C6 glucose for 30 mins, ex vivo in the
loading phase. Subsequently the hearts were subjected to global ischemia (for 0, 5, 10,
15 and 30 mins), flash frozen and metabolites were extracted following established
procedures. Extracted metabolites were quantitated in spectra of 1H heteronuclear single
quantum coherence (HSQC) and 1H spectra with presaturation (PRESAT), respectively.
All quantitation is normalized to the dry residue protein weight (umol/g). In HSQC spectra,
metabolites assessed are linked to

13

C directly, whereas it is linked to total amount of

molecule in PRESAT spectra.
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We found that in HSQC spectra, 13C-labeled lactate production increased in both
of WT and Doxy-off-induced HIF-1α hearts during ischemia (Figure 2.1B). However, the
upward trend is interrupted in WT hearts at 15 mins, while 13C-labeled lactate production
continues and is significantly elevated in HIF-1α hearts at 30 mins of ischemia. This is
consistent with the increased glycolytic flux that we and others, have previously noted
accompanies HIF-1α expression (4, 22). Given that we are examining isolated hearts
undergoing global ischemia, glycogen is the only acknowledged source of available
glucose reserves. Accordingly, 13C-labeled glycogen levels in WT and HIF-1α hearts were
assessed at indicated ischemic times in HSQC spectra (Figure 2.1A). As expected
glycogen glucose reserves are depleted rapidly in WT hearts during ischemia. In stark
contrast, HIF-1α hearts maintained glycogen levels at pre-ischemic levels after 30 mins
of ischemia. These striking results were followed by the assessment of PRESAT spectra
glycogen levels (Figure 2.1C), which measures the total amount of glycogen (12C and 13Clabeled glycogen).

13

C-labeled glycogen levels of satellite B in PRESAT spectra were

measured as well (Figure 2.1E). Similar to the HSQC spectra, 13C-labeled glycogen levels
are maintained to a remarkable extent in HIF-1α hearts during ischemia. Indicating
enhanced glycolytic flux, 13C-lactate production was elevated in the HIF-1α as compared
to WT hearts, especially after 15 mins of ischemia where lactate levels continued to rise
in the HIF-1α hearts while peaking within 5-10 mins of ischemia in WT hearts (Figure 2.1B,
D, and F). In addition, lactate levels were confirmed to be significantly elevated in

13

C-

labeled satellite A and satellite B in HIF-1α hearts at 30 mins of ischemia, compared to
WT (Figure 2.1D and F).
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Figure 2.1: Glycogen Reserves Maintained despite Increased Lactic Acid Production by HIF-1αexpressing Hearts for up to 30 mins of Ischemia. Langerdorff perfused hearts were loaded with
U-13C6 glucose for 30 mins and then subjected to the indicated times for ischemia.

13

C-labeled

1

metabolites derived from WT and HIF-1α mouse hearts were quantitated in H heteronuclear
single quantum coherence (HSQC) spectra by NMR spectroscopy (Figure 1, A, B). Assessment
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of (A) glycogen levels and (B) lactic acid production in heart tissues at corresponding ischemic
times. The glycogen levels are expressed as the percentage of change relative to pre-ischemic
value.
12

C- and

13

C-labeled metabolites are able to be determined synchronously in 1H spectra with

presaturation (PRESAT) by NMR spectroscopy (Figure 1, C-F). (C)
(E)

13

C-labeled glycogen levels, and (D, F)

13

12

C-labeled glycogen levels,

C-labeled lactic acid production in WT and HIF-1α-

PPN/tTA mouse hearts are shown at indicated ischemic times. All glycogen levels are expressed
as the percentage change relative to pre-ischemic value. * P<0.05 vs WT at corresponding
ischemic times; n= 3-5 hearts.

Active gluconeogenesis is responsible for the maintenance of glycogen levels and
glucose:glycogen turnover at later times of ischemia in the HIF-1α-expressing
heart.
We next investigated 13C-labeled isotopologues of metabolites using IC-MS.
13

C-labeled metabolites of glucose are shown (Figure 2.3). During ischemia, glycolysis

of 13C-labeled glucose increases as a compensatory ATP source in hearts during
ischemia, explaining the elevated lactate production in HIF-1α hearts, compared with
WT. The maintenance of glycogen levels suggested an unexpected source of glucose is
present in what is an essentially closed perfusion system. Accordingly, we investigated
the presence of gluconeogenesis intermedates. That is, metabolites labeled with three
carbons (13C-[m+3]), such as Fructose 1,6-bisphosphate, Fructose 6-phosphate,
Glucose 6-phosphate, and Glucose 1-phosphate, are considered as 13C-labeled
glyconeogenic intermediates (Figure 2.3). We found that Glucose 6-phosphate [m+3]
and Fructose 6-phosphate [m+3] increased significantly in HIF-1α hearts at 30 mins of
ischemia, compared with WT hearts. We also observed that Fructose 1,6-bisphosphate
[m+3] was elevated significantly in HIF-1α hearts at 15 mins of ischemia, compared with
WT (Figure 2.2).
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Figure 2.2: Elevated 13C-labeled Gluconeogenetic Intermediates [m+3] in HIF-1α Ischemic Hearts.
13

C-labeled gluconeogenetic intermediates are determined using IC-MS. (A) glucose-6-

phosphate, m+3 (G6P). (B) fructose-6-phosphate, m+3 (F6P). (C) fructose 1-6-bisphosphate,
m+3 (F 1,6-BP). * P<0.05 vs WT at corresponding ischemic period; n= 3-5 hearts.
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Figure 2.3: Schematic viewing of U-13C-glucose metabolism in heart. Black dots indicate

13

C-

atoms and grey dots indicate 12C-atoms. In cytosol, U-13C-labeled glucose is phosphorylated and
converted to [m+6] 13C-labeled G6P, F6P, F1,6-BP, then split up to [m+3] 13C-labeled DHAP (not
shown) and GAP. Eventually, [m+3]
converted into [m+3]

13

13

C-atom will be passed into PEP and pyruvate that can be

C-labeled lactate and alanine under anaerobic condition. Pyruvate is

actively transported into the mitochondria, thereafter in the matrix, there are 2 different routes. 1.
pyruvate could be converted into [m+2] 13C-labeled acetyl-CoA by the PDH complex. acetyl-CoA
brings the acetyl group into the TCA cycle and then produce ATP by the oxidative phosphorylation
under the aerobic conditions, acetyl-CoA is also precursors for de novo biosynthesis of fatty acids
and cholesterol, [m+2] and [m+4] OAA will be produced by this way (not shown). 2. pyruvate could
be converted directly by PC to [m+3]

13

C-labeled OAA. Since OAA is limited to across inner

membrane of the mitochondria, so it needs to be transported by the malate-aspartate shuttle into
the cytosol, there, PEPCK de-carboxylates and phosphorylates OAA for its conversion to [m+2]
(not shown) and [m+3] 13C-labeled PEP. Then 1-molecular [m+3] 13C-labeled GAP combines with
1-molecular endogenous 12C-labeled GAP to generate [m+3] 13C-labeled F1,6-BP, F6P, G6P, and
glucose through the gluconeogenesis. This glucose production could contribute to the increased
glycogen level by glycogenesis in HIF-1α heart. (GULT: Glucose transporter, G6P: glucose 6phosphate,

F6P:

Fructose

6-phosphate,

F1,6-BP:

Fructose

1,6-bisphosphate,

DHAP:

Dihydroxyacetone phosphate, GAP: Glyceraldehyde 3-phosphate, PEP: Phosphoenolpyruvate,
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PDH: Pyruvate dehydrogenase, HK: Hexokinase, PFK: phosphofructokinase, PK: pyruvate
kinase, LDH: Lactate Dehydrogenase, TCA cycle: tricarboxylic acid cycle, OAA: oxaloacetate, PC:
pyruvate carboxylase, PEPCK: phosphoenolpyruvate carboxykinase, FBP: fructose 1,6bisphosphatase, G6PC: glucose 6-phosphatase.)

HIF-1α-expressing hearts more effectively mobilize glycogen synthesis during
Ischemia.
The continued incorporation of 13C-glucose into glycogen even at late times of
ischemia coupled to the continued accumulation of lactate suggests that the HIF-1α
hearts were more effective at mobilizing glucose from glycogen. Accordingly, the status
of glycogen synthase (GS) phosphorylation was examined. P-GS is inactivated and
favors glucose mobilization (Figure 2.4). We observed that in hearts, the phosphorglycogen synthase is dynamically regulated by ischemia and significantly induced by
HIF-1α.
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Figure 2.4: Enhanced glycolytic flux in HIF-1α-expressing heart during ischemia. Tissue samples
from WT and HIF-1α mice hearts were collected following various ischemic periods (0, 5, 10, 15,
and 30 mins) for Western Blotting analysis. (A) the protein expression of phosphor-glycogen
synthase (pGS) as determined for these indicated heart groups. (B) quantification of band
intensity was performed in imageJ. * P<0.05 vs WT at corresponding ischemic period; n= 4.

DISCUSSION
A considerable amount of research has demonstrated the protective effect of HIF1α against ischemia in heart (4, 15, 16). During chronic myocardial ischemia,
downregulation of fatty acids and ketone body oxidation is accompanied by upregulation
of substrate preference toward glucose utilization (17). Hence it is of acute interest to
understand the role of glucose metabolism in myocardial tolerance to hypoxic stress. It is
well established that HIF-1α increases the glycolytic capacity by positively targeting
glycolytic enzyme expression. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
Hexokinase 1/2 (HK1/2) and Triosephosphate isomerase (TPI) under anaerobic, or
aerobic conditions (18, 19, 20). In these studies, we find that that lactate production is
enhanced in HIF-1α hearts, and that

13

C incorporation of lactate continues for up to 30

mins of ischemia. This is consistent with our previous data where we showed that lactate
production in 6D-induced HIF-1α-PPN mouse hearts following ischemia is significantly
elevated (4). Taken together the findings indicate that HIF-1α hearts are more effective
at maintaining glycolytic activity during total global heart ischemia. We will discuss the
reasons for this below.
Our previous work has demonstrated that the purine nucleotide cycle (PNC), a
AMP salvage pathway is upregulated by HIF-1α. The PNC generates fumarate from
aspartate during instances where AMP levels rise, such as strenuous exercise or
ischemia (31). We have also shown that the PHD-pathway/HIF-1α confers upon myocytes
32

the ability to perform anaerobic mitochondrial respiration using fumarate as an electron
acceptor. In this scenario mitochondrial complex II reduces fumarate to succinate. This
allows for continued electron flux through complex I when oxygen is absent. These
mechanisms probably result in two major consequences that impact glycolysis. Firstly,
during ischemia, NAD+ continues to be regenerated, thus allowing glycolysis to proceed
unimpeded. We believe that this accounts, in part, for the findings that lactate continues
to accumulate and incorporate 13C label even after 30 mins of global ischemia in the HIF1α hearts.

Secondly, AMP deaminase, the rate-limiting enzyme of the PNC that is

upregulated by HIF-1α has been posited to positively regulate phosphofructokinase (31).
Ammonium ions produced by AMP deaminase activate phosphofructokinase, which in
turn, stimulates glycolysis. Clearly, HIF-1α exerts its effects through multiple regulatory
mechanisms to many metabolic pathways in order to situate the myocyte to tolerate a low
oxygen/substrate environment.
The most remarkable finding of this study is the extent to which 13C-labeled and
total glycogen levels were maintained in HIF-1α hearts at ischemic times of up to 30 mins.
This surprising finding suggested an unexpected source of glucose in the un-perfused
ischemic HIF-1α heart. Accordingly, we investigated the levels of gluconeogenic
intermediates (i.e. [M+3] isotopologues of glycolytic intermediates; consult figure 2.2 and
2.3) in the HIF-1α hearts. Indeed, we find that the levels of gluconeogenic intermediate
metabolites are highly elevated in the HIF-1α hearts during ischemia as compared to the
WT hearts. Taken together these findings indicate that active gluconeogenesis accounts
for the failure to deplete glycogen and glucose and fructose phosphate species in the
HIF-1α hearts.
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Two ATP equivalents are produced in anaerobic glycolysis. In contrast, 4 ATP
and 2 GTP are consumed to produce glucose via gluconeogenesis. The HIF-1α heart
does have sources of anaerobically produced high energy phosphates, including the
aforementioned “fumarate respiration”, that are not available to the naïve WT hearts.
Nonetheless, the question arises, what advantage might arise to expending scarce ATP
to maintain glucose/glycogen levels and glycolytic activity. We believe the answer may
lie in the nature of glycolytic ATP utilization versus oxidatively produced ATP. Unlike
myocardial contractile function, which is supported primarily by energy derived oxidative
phosphorylation, sarcolemma ion channel function (e.g. Na+-K+ pump) of the
cardiomyocyte is preferentially fueled by glycolytic ATP production (28, 29). The
functional compartmentalization is achieved through the location of key enzymes in the
membrane or adjacent cytoskeleton region of cell (30). Loss of ionic homeostasis, either
at the sarcolemma, or at the mitochondrial inner membrane is associated with irreversible
cellular damage. In this view, continued glycolytic metabolism may represent a key
requisite for cellular survival.
In summary, we show that HIF-1α upregulates and prolongs glycolytic flux in
heart for longer periods (i.e. 30 mins) of ischemia via activating gluconeogenesis. The
preservation of glycogen in the HIF-1α heart provides uninterrupted anaerobic energy
supply that primarily fuels ionic homeostasis and, which may prevent cardiomyocyte injury
mediated by ionic gradient dissolution in ischemia.
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ABSTRACT
As the largest endocrine organ, adipose tissue secretes many bioactive molecules that
circulate in the blood, collectively termed adipokines. Efforts to identify such metabolic
regulators have led to the discovery of a family of secreted proteins, designated as C1q
tumor necrosis factor (TNF)-related proteins (CTRPs). The CTRP proteins, adiponectin,
TNF-alpha, as well as other proteins with the distinct C1q domain are collectively
grouped together as the C1q/TNF superfamily. Reflecting profound biological potency,
the initial characterization of these adipose tissue-derived CTRP factors finds wideranging effects upon metabolism, inflammation, and survival-signaling in multiple tissue
types. CTRP3 (also known as CORS26, cartducin, or cartonectin) is a unique member
of this adipokine family. In this review we provide a comprehensive overview of the
research concerning the expression, regulation, and physiological function of CTRP3.
INTRODUCTION
Since the discovery of Leptin in 1994 and then later adiponectin there has been
a fundamental shift in how adipose tissue is viewed within the medical and research
community, as an active endocrine organ which effects human health and physiology
(57, 87). In 2004 Wong et al. characterized a novel family of adipose tissue-derived
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cytokines, collectively called adipokines, referred to as Complement C1q Tumor
necrosis factor-Related Proteins (CTRPs) (76), like adiponectin and tumor necrosis
factor (TNF) these CTRPs all contain a C1q globular domain and are characterized
together as the C1q/TNF superfamily (62). To date, this superfamily has been
documented to have a wide range and opposing effects on metabolism, food intake,
inflammation, tumor metastasis, apoptosis, vascular disorders, ischemic injury, and
even sexual reproduction (7, 8, 25, 29, 30, 49, 51, 57, 62, 64, 68, 69, 74-76, 81, 84, 89).
The purpose of this review is to carefully summarize the research that has been
accomplished on one of these proteins, CTRP3. A list of abbreviations used in this
article is found in Table 3.1.
Table 3.1: Abbreviations
SP-1: specificity protein 1
CTRP3: C1q TNF Related Protein 3
LPS: Lipopolysaccharide
TLR: toll-like receptor
MCP-1: monocyte chemotactic protein 1
PPAR: peroxisome proliferator-activated receptor
pIgA: polymeric Immunoglobulin A
RANKL: Receptor activator of nuclear factor kappa-B ligand
TNF: Tumor necrosis factor
IL-6: Interleukin-6
AP-1: Activator protein 1
c-FOS: Fos proto-oncogene
Pit-1a: POU domain, class 1, transcription factor 1
C/EBP-a/b: CCAAT-enhancer-binding proteins-alpha/beta
MyoD: Myogenic Differentiation
c-JUN: Jun proto-oncogene, AP-1 transcription factor subunit
TY-IID: Transcription factor II D – “TATAA”
CREB: cAMP response element-binding protein
GATA-1: GATA-binding factor 1
SRY: Sex-determining region Y
Sox-5: SRY-related HMG-box 5
c-Myc: similar to myelocytomatosis viral oncogene
RXR: Retinoid X receptor
PGC-1α: Peroxisome proliferators activated receptor-γ co-activator-1α
NRF-1/NRF-2: nuclear respiratory factor 1/2
TFAM: mitochondrial transcription factor A
TBXAS1: thromboxane A synthase 1
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HUVEC: Human umbilical vascular endothelial cells
ROS: Reactive oxygen species
TGF-β: Transforming growth factor beta

History of CTRP3
Initial discovery
CTRP3 was first discovered in 2001(43) in C3H10T1/2 mouse mesenchymal
stem cells treated to induce chondrogenic differentiation. Because of its size and 23
Gly-X-Y repeats in the N-terminal collagen domain it was originally named CORS26
(Collagenous repeat-containing sequence 26 kDa protein). Later Wong et al. (2004)
identified CTRP3 as a member of a family of highly conserved adiponectin paralogs
designated as CTRPs and CORS26 was renamed CTRP3(76). Alternative names that
have been used for CTRP3 are cartducin (1, 44) and cartonectin (56, 73), both due to
the detection of CTRP3 expression in developing cartilage.
Structure
Analysis of the primary structure predicts that CTRP3 is a highly hydrophilic
secreted protein, with an N-terminal hydrophobic signal peptide, and no transmembrane
domains (43). Experimental work confirms that CTRP3 is a secreted protein and
circulates in the blood, which indicates that the physiological function of CTRP3 occurs
through endocrine mechanisms (51, 75). Additionally, CTRP3 has a series of N-terminal
Collagenous repeats (Gly-X-Y), and a highly conserved C-terminal globular domain
(76), thus placing CTRP3 within the expanding C1q TNF Superfamily (62) (Figure 3.1).
CTRP3 shares sequence homology with adiponectin (38% in mouse and 36% in
human), and is highly conserved (95.9% identity between human and mouse proteins)
(36). Additionally, there are two splice variants of CTRP3 that have been identified. The
longer splice variant, designated as CTRP3B, encodes an extra 73 N-terminal amino
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acids due to the retention of intron 1. CTRP3B contains a highly conserved N-linked
glycosylation site that is not present on the original splice variant, CTRP3A (51). At this
time the functional significance of the splice variants of CTRP3 is unknown as research
has focused almost exclusively on CTRP3A. Regardless, both CTRP3A and CTRP3B
are secreted proteins which are detectable in human serum. Although only CTRP3A
has been detected in mouse serum, both variants are expressed in mouse adipose
tissue (51, 75). One of the reasons for the difficulty in detecting the CTRP3B variant is
that unlike CTRP3A, CTRP3B degrades rapidly unless it forms a higher order oligomer
with CTRP3A (51).

Figure 3.1: Structural Overview of CTRP3. Two splice variants were identified and designated
as CTRP3A and CTRP3B. B, organization of the CTRP3A and CTRP3B genes and proteins.
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The human CTRP3A gene is 25.3 kb in size, consists of six exons and five introns, and is
located on chromosome 5p13. Exons 1, 2, 3, 4, 5, and 6 of the CTRP3A gene are 171, 112,
155, 130, 100, and 2,885 bp in size, respectively. The size of each intron is also indicated. Exon
1B (gray square) contains a 219-nucleotide sequence found in CTRP3B cDNA, coding for an
extra 73 amino acid residues. A potential N-linked glycosylation site is circled. The consensus
splice donors are shown in italic type. This figure was originally published in The Journal of
Biological Chemistry (51) and image reproduced according to the copyright policy of the
ASBMB.

CTRP3 is endogenously co-expressed in many tissues with other proteins
within the C1q TNF superfamily. However, CTRP3 is unique as it does not form heterooligomeric complexes with adiponectin or any other CTRP protein (76). Most CTRP
proteins will form hetero-oligomers with adiponectin or at least 1 other CTRP protein
when coexpressed (75, 76). However, higher-order oligomers are the primary form by
which CTRP3 is found circulating in either human or mouse serum, indicating that
CTRP3 high-order oligomeric complexes occur solely between its two splice variants,
CTRP3A and CTRP3B (51). While the significance of these posttranslational
modifications and higher order structure formations have yet to be explored, it is likely
that these modifications influence the function of CTRP3. Therefore, it is important to
differentiate between functional studies and experimental findings gleaned from
bacterial-produced compared with other types of recombinant CTRP3 protein. Bacterialproduced recombinant CTRP3 protein does not possess the potentially physiologically
relevant post-translational modifications or multimeric structures, and may explain any
observed lack of biological activity (19, 61).
Recently using the novel ligand-receptor capture method, and mammalian-cell
expressed CTRP3, Li et al. (2016) (41) identified Lysosomal-associated membrane
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protein 1 (LAMP-1) and Lysosome membrane protein 2 (LIMP II) as potential receptors
for CTRP3. Although it remains to be determined whether either of these proteins
directly mediate the intercellular effects of CTRP3 or act as co-receptors for a yet
unidentified protein, both LAMP1 and LIMPII are widely expressed in a number of
different tissues corresponding to the variety of functions attributed to CTRP3. A
comprehensive list of in vitro functions documented for CTRP3 is listed in Table 3.2.
CTRP3 may also act without directly initiating intracellular action but rather through
inhibiting the binding of other ligands. For example, lipopolysaccharide (LPS) is a
potent endotoxin that binds to Toll-like receptor 4 (TLR4) and promotes a cellular
inflammatory response. However, even though CTRP3 does not bind directly to either
LPS or TLR4, CTRP3 prevents their interaction through an unestablished mechanism
(30).
Table 3.2: Complete Summary of the In Vitro Functions of CTRP3
Cell line
N1511 (mouse
chondrogenic
progenitor)

Citation
Akiyama et
al (2006)(1)

Type of treatment
10 µg/ml [E. Coli produced
His6-tagged signal peptide
removed]

MSS31 (mouse
endothelial cells)

Akiyama (2)
et al (2007)

LM8 (mouse
osteosarcoma cell
line)

Akiyama et
al (2009)(3)

1-5 µg/ml [E. Coli produced
His6-tagged signal peptide
removed]
2-10 µg/ml [E. Coli produced
His6-tagged signal peptide
removed]

NOHS (mouse
osteosarcoma cell
line)

Akiyama et
al (2009)(3)

2-10 µg/ml [E. Coli produced
His6-tagged signal peptide
removed]

Rat vascular
smooth muscle
cells (VSMCs)

Feng et al
(2016)(15)

Human globular CTRP3
(Aviscera Bioscience) Catalog
# not reported
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Effect
Increased ERK ½, and Akt
phosphorylation from 5 min-1
hour, but not JNK or p38
MAPK
↑ Proliferation and migration, ↑
ERK1/2 & MAPK p38 within
15 minutes.
CTRP3 treatment ↑
proliferation and ↑ ERK1/2
phosphorylation with no effect
on migration or p38, JNK1/2,
or Akt phosporylation.
CTRP3 treatment ↑
proliferation and ↑ ERK1/2
phosphorylation with no effect
on migration or p38, JNK1/2,
or Akt.
CTRP3 promotes ATP
synthesis, oxidative
phosphorylation complex
proteins, and

Human primary
colonic lamina
propria
fibroblasts
(CLPF)

Hofmann et
al 2011(21)

Recombinant CTRP-3 (High
Five insect cells)

RWPE-1 prostate
cells (ATCC
Number CRL11609)

Hou Et al.
2015(23)

Mammalian expressed CTRP3
(3, 10, or 30 µg/ml)

bone marrow
macrophages
(BMM)

Kim et al
(2015)(27)

Recombinant human CTRP3
was purchased from AdipoGen
(Catalog number not reported)

Adipocyte (3T3L1)

Kopp et al.
2010(30)

1-10 µg/ml Recombinant full
length CTRP3 (H5 insect
cells)

Primary Human
monocytes

Kopp, A. et
al.(2010)(30
)

1 µg/ml Recombinant full
length CTRP3 (H5 insect
cells)
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ROS levels; whereas siRNA
knockdown
reduces ATP and oxidative
phosphorylation
complex proteins levels
Significantly and dosedependently reduced LPSinduced IL-8 secretion in CLPF
within 8 hours after LPS
exposure, whereas LPSinduced IL-6 and TNF release
was not affected. CTRP-3
inhibited TGF-β production
and the expression of CTGF
and collagen I in CLPF,
whereas collagen III expression
remained unchanged.
Increased cell number in a dose
dependent manner at 24-72
hours, and 10 µg/ml prevented
apoptosis. Cytokeratin-19,
GLRX3 and DDAH1 were
upregulated and cytokeratin-17
and 14-3-3 sigma were
downregulated proteins in
CTRP3-treated cells.
↓ osteoclast differentiation
from BMM treated with IL-1,
1,25(OH2)D3, Receptor
activator of nuclear factor
kappa-B ligand (RANKL),
further CTRP3 prevented
mature osteoclasts from
reabsorbing bone
Suppressed LPS, lauric acid,
TLR1/2, or TLR3 ligandinduced MCP-1 release.
CTRP3 had no effect on
TLR2/6 ligand-induced MCP-1
release. Further, siRNA
knockdown of CTRP3
increased MCP-1 release and
decreased adiponectin secretion
and reduced lipid
accumulation.
Suppressed LPS-induced MIF
& CCL4 release in lean
subjects, & MCP-1 in
monocytes from both diabetic
and leans subjects. Prevents

Primary Human
monocytes

Kopp, A. et
al.(2010)(31
)

1 µg/ml Recombinant full
length CTRP3 (H5 insect
cells)

Adipocyte (3T3L1)

Li et al
2014(38)

Recombinant CTRP3 (uncited
origin)

Adipocyte (3T3L1)

Li et al
2014(39)

Mammalian expressed
recombinant CTRP3 (250
ng/mL)

Adipocyte (3T3L1)
Adventitial
fibroblasts

Schmid et al
(2012)(59)

siRNA knockdown of CTRP3

Lin et al
(2014)(42)

CTRP3 protein (10 µg/ml)
(source/type of CTRP3 was
not reported)

HSC-2/8 (human
chondrocytes)

Maeda et al
(2006)(44)

N1511 (mouse
chondrogenic
progenitor)
TM3 mouse
Leydig Cells

Maeda et al
(2006)(44)

10 µg/ml [E. Coli produced
His6-tagged signal peptide
removed]
2-10 µg/ml [E. Coli produced
His6-tagged signal peptide
removed]
Mammalian expressed full
length (3-30 ug/ml)

Adipocyte (3T3L1)

Schmid et al
2012(59)

siRNA knockdown of CTRP3

Adipocyte (3T3L1)

Schmid et al
2013(58)

siRNA-mediated cellular
knockdown of CTRP-3

Adipose tissue
collected from
control (n=3) or

Schmid et
al.
(2012)(59)

Otani et al
(2012)(47)
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Lauric acid induced release of
IL-6 and TNF
↓ LPS-induced secretion of IL6 in monocytes from control
but not T2D. CTRP3 did not
significantly affect TNF
secretion.
increased adipocyte glucose
uptake and decreased TNF and
IL6 secretion in insulin
resistant 3T3-L1A
↑ the secretion of adiponectin,
leptin, visfatin, and apelin
with peak detectable effect at
12 hours (effects prevented by
the addition of an AMPK
inhibitor).
Reduced resistin secretion and
lipolysis.
CTRP3 prevents TGF-β1
induced fibroblasts phenotypic
Conversion, proliferation,
migration, collagen I
expression, and connective
tissue growth factor (all
indicators of inappropriate of
vascular remodeling and
neointima formation).
Increase proliferation
Increase proliferation
Dose responsive ↑ testosterone
production, ↑ steroidogenic
acute regulatory protein mRNA
and protein levels
siRNA knockdown of CTRP3
reduced resistin secretion and
lipolysis.
siRNA-mediated cellular
knockdown of CTRP-3 in
adipocytes resulted in an
upregulation of CTRP-5
expression.
CTRP3 protein levels were
higher in subcutaneous
adipocytes from an obese
compared with lean donor, no

diabetic (n=3)
female donors)
THP-1 (human Acute Monocytic
Leukemia cell
line)
Adipocyte (3T3L1)

Weigert et
al 2005(70)

1 µg/ml Recombinant full
length CTRP3 (H5 insect
cells)

Wolfing et
al
(2008)(73)

10 ng/ml Recombinant full
length CTRP3 (H5 insect
cells)

Primary cultured
adult rat cardiac
fibroblast (CF)

Wu et al
2015(77)

2 µg/ml Recombinant human
gCTRP3 (Aviscera
Bioscience; 00082-01-100; E.
Coli expressed); also used
siRNA knockdown of CTRP3

Cardiomyocytes
(adult mouse)

Yi et al
(2012)(81)

Bacterial expressed globular
domain of Mouse CTRP3

human umbilical
vascular
endothelial cells
(HUVECs)

Yi et al
(2012)(81)

Bacterial expressed globular
domain of Mouse CTRP3
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differences were observed from
visceral adipocytes. (Note:
small sample size, n=3)
Suppressed LPS induced: IL-6
& TNF mRNA and release.
increase adiponectin and
resistin secretion but not
promoter activity with no effect
on IL-6 (no effect on humanderived adipocytes).
Inhibited TGF-β1α-induced αSMA, SM22α, SM22α,
collagen I, collagen III, and
connective tissue growth factor
(CTGF) expression [markers
for myofibroblast
differentiation]. Whereas,
SiRNA knockdown of CTRP3
increased TGF-β1-induced αsmooth muscle actin (α-SMA)
and smooth muscle 22α
(SM22α) collagen I, collagen
III, and CTGF expression.
Further CTRP3 attenuated
TGF-β1 induced-elevations in
phosphor-Smad3 (Ser204).
CTRP3 upregulated levels of
phosphorylated Akt, HIF1α,
and VEGF. Further
cardiomyocyte hypoxiainduced apoptosis was
attenuated with condition
media from 3t3-L1A
adipocytes, however this effect
was abolished when the
conditioned media came from
3T3-L1a cells treated with
CTRP3 siRNA.
CTRP3 had no effect on tube
formation, Akt phosphorylation
or HIF1α or VEGF expression.
These results suggest that the in
vivo proangiogenic effect of
CTRP3 is no through direct
mechanisms on endothelial
cells. Further, treatment of
HUVECs cell with condition

Primary meckel’s
cartilage
human mesangial
cells (HMCs)

YokohamaTamaki et al
(2011)(82)
Zhang et al
(2016)(86)

Neonatal rat
ventricular
myocytes

Zhang et al
2016(85)

Human mesangial
cells (HMCs)

Zhang et al
(2016)(86)

Rat Cultured
Carotid Arterial
Rings

Zhou et al
(2014)(90)

Rat vascular
smooth muscle
cells (VSMCs)

Zhou et al
(2014)(90)

Knock-down of CTRP3
(antisense
ogliodeoxynucleotide)
Full length human CTRP3
(PubMed No. NM_030945.2)
adenovirus mediated
overexpression
0.5 – 4 µg/ml Human
recombinant globular and fulllength CTRP3 (Aviscera
Bioscience) Catalog # not
reported
Treated with Serum polymeric
IgA (pIgA) from control or
IgAN patients
(1, 2, and 4 µg/mL)
Recombinant human globular
domain CTRP3 Aviscera
Bioscience (00082-01-100,
Santa Clara, CA)
(1, 2, and 4 µg/mL)
Recombinant human globular
domain CTRP3 Aviscera
Bioscience (00082-01-100,
Santa Clara, CA)

media from primary
cardiomyocytes treated with
CTRP3 significantly enhanced
HUVEC tube formation.
Caused severe curvature
deformation and suppressed
growth.
↓ pIgA-induce IL-6 and TGFbeta secretion from HMC cells.
Both increased the expression
of PGC-1α, nuclear respiratory
factor 1&2, and markers of
mitochondrial biogenesis
pIgA markedly increased IL-6
and TGF-β in HMCs, which
were suppressed after AdCTRP3 transfection.
CTRP3 Promotes Vascular
Calcification in
High-Phosphate Cultured
Carotid Arterial Rings.
CTRP3 Promotes βGlycerophosphate–Induced
VSMC Calcification In Vitro
and promoted the phenotypic
transition from contractile to
osteogenic phenotype. CTRP3
increases mitochondrial
Reactive oxygen species levels
in VSMC.

Regulation
Analysis of the upstream untranslated region for CTRP3 identified a number of
putative consensus sequences for transcription factor regulation of CTRP3 expression.
The proximal region of the CTRP3 promoter is highly conserved between rodent and
human (28), indicating that there are conserved functional regulation sites. These
predicted regulatory sites include loci for the following transcription factors: specificity
protein 1 (SP-1); Activator protein 1 (AP-1); Peroxisome proliferator-activated receptor
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(PPAR); Fos proto-oncogene (c-FOS); POU domain, class 1, transcription factor 1 (Pit1a); CCAAT-enhancer-binding proteins-alpha/beta (C/EBP-α/β); Myogenic
Differentiation (MyoD); c-JUN; Transcription factor II D – “TATAA” box (TY-IID); cAMP
response element-binding protein (CREB); GATA-binding factor 1 (GATA-1); Sexdetermining region Y (SRY); SRY-related HMG-box 5 (Sox-5); similar to
myelocytomatosis viral oncogene (c-Myc); and Retinoid X receptor (RXR) (53-55).
However, to date, only a few transcription factors have been demonstrated to regulate
CTRP3 expression experimentally: c-FOS, SP-1, c-JUN, and PPAR-gamma.
Although CTRP3, SP-1 and PPAR-gamma are induced during adipocyte differentiation,
promoter activity assays demonstrate that PPAR-gamma, SP-1, and c-FOS are all
negative regulators of CTRP3 expression (53, 56). Electrophoretic mobility shift assays
confirmed that both SP-1 and PPAR-gamma (but not SRY, c-FOS, C/EBPβ, or PPARalpha) bind to the promoter region for CTRP3. To date only the transcription factor cJun has been shown to be an unequivocal positive regulator for CTRP3 transcription
(28). The transcription factor c-Jun is one of three Jun family proteins making up the
activator protein-1 (AP-1) transcription factor group. Chromatin immunoprecipitation
assay confirmed that c-Jun binds to the AP-1 region (-184/-177) of CTRP3 (28),
whereas, other Jun and Fos members JunB, JunD, FosB, Fra-1 and Fra-2 were tested
by a reporter gene assay and had no effect on CTRP3 promoter activity (28). Further,
treatment of adipocytes, in vitro, or diet-induced obese rats, in vivo, with the glucagonlikepeptide-1 (GLP-1) receptor agonist, Exendin-4 (Ex-4), increased CTRP3 expression
and circulating levels through activation of the Protein kinase A (PKA) pathway (37, 40).
Briefly, the activation of GLP-1 receptor and, the PKA pathway activates a HOB1 motif
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within the A1 activation domain of c-JUN and promotes c-JUN’s binding to the AP-1
region (6). However, the regulation of CTRP3 under physiological conditions in vivo has
not yet been established. Unlike most adipokines, circulating CTRP3 levels are
increased with fasting (51), indicating that CTRP3 levels may be suppressed by either
insulin or activated by glucagon signaling pathways. Further, CTRP3 levels are
negatively associated with insulin and leptin levels in high fat fed mice (51). Taken
together, these data show a potential reciprocal relationship between food intake and
CTRP3. However, the clinical implications have yet to be explored, especially regarding
the significance of the by-phasic regulation of CTRP3 and lipid metabolism.
Tissues expressed
A summary of cell lines, which express CTRP3, in vitro, are listed in Table 3.3.
CTRP3 is not detectable in undifferentiated adipocytes, but can be detected at 4 days of
differentiation (55, 56). These data match in vivo data which shows that CTPR3 is highly
expressed in adipose tissue. In addition, CTRP3 is also detected during development,
starting at mouse embryonic day 15 (43, 75, 76), in developing chondrocytes (43) and
cartilage (44). These data have led to speculation that CTRP3 is essential for
appropriate bone growth and development. This is supported by experimental evidence
that demonstrates that CTRP3 stimulates the proliferation and differentiation of
chondrogenic and osteogenic precursors, inhibits osteoclast activity, and is essential for
appropriate bone formation in vitro (1, 27, 44, 82). However, a clinical association
between abnormal development and deregulation of CTRP3 protein has yet to be
documented. On the other hand, CTRP3 is highly expressed in both osteoscarcoma
and chandroblastoma cell lines but not in the MC3T3-E1 mouse osteoblast-like non-
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cancer cell line (3). These data have led to speculation that elevated CTRP3 level in
adults may be a risk factor and/or biomarker for certain types of cancer, specifically
osteoscarcoma, but again this hypothesis remains to be tested either in vivo or in a
clinical population.
Table 3.3: CTRP3 Expression In Vitro
Cell Line
Adipose tissue
collected from
control (n=3) or
diabetic (n=3) female
donors
N1511 (mouse
chondrogenic
progenitor)
3T3-L1a (mouse preadipocyte)

Reference
Schmid et
al
2012(59)

3T3-L1a (mouse preadipocyte)

Li et al
2015(37)

3T3-L1a (mouse preadipocyte)

Schmid et
al
2012(59)

MC3T3-E1 (mouse
osteoblast-like cell
line; non-cancer)
Human mesangial
cells (HMCs)

Akiyama
et al
2009(3)
Zhang et al
2016(86)

LM8 (mouse
osteosarcoma cell
line)
NOHS (mouse
osteosarcoma cell
line)
Human omental
adipose tissue
explants
TM3 mouse Leydig
Cells

Akiyama
et al
2009(3)
Akiyama
et al
2009(3)
Tan et al
2013(65)

Maeda et
al
2006(44)
Schaffler
et al
2007(56)

Otani et al
2012(47)

Finding
CTRP3 protein levels were higher in subcutaneous adipocytes from
an obese
compared with lean donor, no differences were observed from
visceral
adipocytes. (Note: small sample size, n = 3)
CTRP3 is induced w/ differentiation by TGF-beta
Produce CTRP3 at day 4 differentiation and CTRP3 promoter
activity was suppressed when treated with PPAR ligands:
troglitazone (α/g), fenofibrate (α), but not 15-Deoxy-Delta-12,14prostaglandin J2.
Exendin-fragment 4 (Ex-4), a specific GLP-1 receptor agonist,
specifically used to treat T2D, increased CTRP3 mRNA and protein
whereas Ex-9 (and GLP-1 antagonist) or blocking activation of
PKA (thr197) phosphorylation by H89, a selective antagonist of
PKA, blocked Ex-4 induced increases in CTRP3. Neither H89 nor
Ex-9 had any effect on CTRP3 alone.
CTRP3 is positively regulated by insulin, and inhibited by chronic
LPS-exposure or Intracellular infection of adipocytes by S. aureus.
Further, siRNA knockdown of CTRP3 reduced resistin secretion
and lipolysis.
Neither CTRP3 mRNA or protein was detected
polymeric IgA (pIgA) suppressed CTRP3 mRNA and protein
whereas the IgA1 fractions (mIgA and pIgA) had no effect on
CTRP3. Further, galactose-deficient IgA (gd-IgA; the type of IgA
found in IgAN patients) suppressed CTRP3 mRNA levels even
more than pIgA at identical concentrations (~60% compared with
30%).
CTRP3 mRNA and protein detected.
CTRP3 mRNA and protein detected.
Metformin increased CTRP3 secretion.
Express CTRP3
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In adult mice CTRP3 is considered an adipokine, as it is predominantly
expressed in adipose tissue (55, 56, 75), indicating that CTRP3 may have a functional
role in energy storage and metabolism. However, CTRP3 is also expressed in the lung,
kidneys, spleen, testis, and macrophages with moderate expression in heart, bone,
small intestine, liver, kidney, skeletal muscle, and vascular smooth muscle cells (1, 43,
44, 47, 51, 54, 59, 75, 76, 90). Combined these data indicate that CTRP3 has a variety
of factors which could contribute to its regulation and function. In the following sections
we will detail the experimental evidence regarding the functional activity of CTRP3 in
regards to metabolism, cardiovascular health, inflammation, and growth and
development.
Metabolism, Metabolic disease and CTRP3
Overview
CTRP3 has been documented to have a variety of effects on metabolism. The
complete overview of in vitro effects is listed in Table 3.2. Briefly, CTRP3 increases
adipokine secretion, attenuates inflammatory signaling, promotes proliferation,
increases cellular differentiation, and increases hepatic lipid oxidation (39, 41, 50, 51,
58). Whereas, the in vivo the effects of CTRP3 are less well examined. The summary of
all animal experiments and CTRP3 are listed in Table 3.4. For example, in rodents an
acute injection with recombinant CTRP3 protein decreases serum glucose levels for up
to 8-hours with no change to insulin levels (51). The chronic transgenic overexpression
of CTRP3 had not effect upon glucose levels, which demonstrates the development of a
potential compensatory mechanism (51). On the other hand, both transgenic
overexpression and daily administration of CTRP3 were effective in attenuating high fat
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diet-induced hepatic insulin resistance and hepatic steatosis (50). Conversely, hepatic
triglycerides were elevated in high fat-fed CTRP3 Knockout mice when compared to
high fat-fed wild-type mice (71). Considered together, these data suggest that the
metabolic effects of CTRP3 are specific to the liver, as no changes to metabolism were
observed in skeletal muscle in any experimental (in vivo or in vitro) model examined.
Interestingly, neither transgenic overexpression nor genetic deletion of CTRP3 resulted
in a measurable metabolic effect in mice fed a low fat diet (50, 71), which indicates that
CTRP3 may function specifically to help regulate metabolism in response to elevated
lipid consumption.
Table 3.4: Metabolic Effects of CTRP3 In Vivo
Model
Male rats HFD+low
dose Streptozotocin

Reference
Li et al 2014(40)

CTRP3 Knockout and
collagen-induced
arthritis model
Transgenic CTRP3
overexpression with
low or high fat diet

Murayama et al
(2014)(46)

Acute injection of
CTRP3

Peterson et al
(2010)(50)

Transgenic CTRP3
overexpression with
low or high fat diet

Peterson et al
(2012)(51)

Viral suspension
consisting of 1x10^9
genomic copies of the
lentivirus-CTRP3
(Lenti-CTRP3)

Wang et al
(2016)(67)

Petersen et al
(2016)(48)

Results
CTRP3 mRNA increased between birth and 10
weeks of age. Insulin resistance or T2D
decreased CTRP3 (Protein &mRNA) and
treatment with Ex-4 slightly increased CTRP3.
↑ severe histopathological changes.
LF-diet; ↑ the circulating levels of CCL11,
CXCl9, CXCL10, CCL17, CX3CL1, CCL22,
AND Scd30.
HF-Diet: ↓ circulating levels of IL-5, TNF-α,
sVEGF2, and sVEGFR3, and ↑ circulating
levels soluble gp130.
↓glucose, ↑pAkt and hepatic gluconeogenesis
(specifically PEPCK and G6Pase.
No metabolic effect LF-diet; On HF-diet: mild
shift to lipid oxidation, ↓ hepatic triglyceride
synthesis, ↓ hepatic stenosis, ↑ insulin
sensitivity. ↓ circulating TNF, IL5 and
cholesterol levels and more than doubled
soluble gp130 (sgp130) levels (an inhibitor of
IL-6).
Attenuates Brain Injury after Intracerebral
Hemorrhage via AMPK-Dependent Pathway in
Rat.
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CTRP3 Knockout fed
a high fat diet

Wolf et al (2016)(71)

Mouse model of
myocardial infarction
(MI); Adenovirus
mediated
overexpression of
human full-length
CTRP3

Yi et al 2012(81)

No differences in metabolic factors between KO
and WT, however the liver was smaller with a
higher triglyceride content.
MI reduced adipocyte CTRP3 mRNA and
plasma protein levels. Whereas, Replenishment
of CTRP3 after MI Improves Survival, Cardiac
Function, promotes angiogenesis,

Regardless, the clinical implications of these effects have yet to be explored, as
the reported associations between obesity and/or type 2 diabetes (T2D) with CTRP3
levels are contradictory in the literature. The summary finding of all cross sectional
human studies, which examine CTRP3 levels, are listed in Table 3.5. Briefly, CTRP3
levels are reported to be elevated (12), not different (16, 66), or reduced (5, 14, 52, 65,
72, 83) with obesity and/or T2D. In most reports circulating CTRP3 levels are higher in
women than in men (10, 14, 72, 83), with one exception (52). Further complicating the
relationship between CTRP3 levels and human health, Wager et al. (2016) (66)
reported that CTRP3 levels are elevated with obesity in male but are reciprocally
reduced with obesity in female subjects. This contradictory gender dependent
association of obesity and circulating CTRP3 levels provides some explanation
regarding the conflicting data in the literature, as almost all the reported studies
combined varying proportions of male and female subjects within each experimental
group. Nevertheless, these data demonstrate that there is a gender specific regulation
and function of CTRP3 that needs to be explored in more detail. Further, all of these
studies have examined the total amount of CTRP3 with no attention being given to the
different splice variants or in the multimeric structures of the circulating CTRP3. This is
worth noting as high molecular weight adiponectin is thought to be the active form (20,
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32), and similarly the different splice variants and multimeric structure may also
contribute to the function of CTRP3. Lastly, the associations between circulating CTRP3
levels (splice variants and multimeric structures) and hepatic steatosis in human
subjects have not been explored even though animal experiments have shown a
specific hepatic effect of both CTRP3A and CTRP3B (51).
Table 3.5: Cross-Sectional Studies Regarding CTRP3 Levels
Population
(Male:Female)
Newly diagnosed T2D
(25:22) vs Control (35:28)

Referenc
e
Ban et al
2014(5)

126 singleton live births
(67:59)

Chen et
al.
2016(9)
Choi et al
2012(12)

Control (40:79),
prediabetic (40:71), or
T2D (54:65)

Result
CTRP3 levels were lower in T2D (150 ng/ml) vs control (249
ng/ml). CTRP3 was negatively associated with C-reactive protein
levels and positively associated with insulin levels in control
subjects. No associations were observed in T2D.
CTRP3 was positively correlated with Ponderal index (a
measurement of thinness) and birth weight.
Overall: CTRP3 levels were positively correlated with Total
cholesterol, fasting blood glucose, AST and ALT, Creatinine, and Creactive protein levels, and negatively correlated with estimated
glomerular filtration rate. CTRP3 increased significantly with T2D
(Normal 273, prediabetes 482, and T2D 516 ng/ml).
CTRP3 levels were higher in women than men. Independently
associated with age, sex, and triglyceride, LDL cholesterol,
adiponectin, and retinol-binding protein 4 (RBP4) levels.

453 nondiabetic Korean
adults (137:316)

Choi et
al.
2013(10)

362 Korean adults: with
acute coronary syndrome
(49:20), stable angina
pectoris (58:27), or control
subjects (137:71)

Choi et
al.
2014(11)

CTRP-3 levels were lower in patients with acute coronary syndrome
or stable angina pectoris compared to control subjects. CTRP-3
levels negatively associated with glucose and C-reactive protein
positively associated with HDL-cholesterol and adiponectin.

Newly diagnosed obese
and hypertensive patients
(124:83)

Deng et
al
2015(14)

Obese (33:39) and
T2D (34:35)

Flehmig
et al
2014(16)
Li et al
2015(34)

Regardless of groups women had higher CTRP3 levels than men.
Both obesity and High blood pressure were associated with lower
CTRP3 levels, there was no further reduction in obesity combined
with High BP
No difference in CTRP3 levels with obesity or T2D. Of the 69 T2D,
46 were taking metformin and CTRP3 levels were increased with
metformin (267 vs 343 ng/mL).
CTRP3 levels (COPD 950 ng/mL; Control 820 ng/mL) had no
correlation to lung function. No association between CTRP-3 and
CRP, TNF-α, or adiponectin.

COPD patients (50:23)
and healthy controls
(29:25)
Lean (25:20), obese
(19:24), T2D (17:24), and
Obese+T2D (22:23)

Qu et al
2015(52)

No difference in CTRP3 between men and women (397.51 ± 122.67
vs 416.17 ± 131.24 ng/mL,). CTRP3 levels were reduced in obese
and T2D and further reduced in obese+T2D. CTRP3 levels were
negatively associated with IL-6 levels, HOMA-IR, and HbA1c.
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Women with Polycystic
ovary syndrome (PCOS)

Tan et al.
2013(65)

Lean (20:40) and obese
(6:44)

Wolf et
al
2015(72)
Yoo et
al.
2013(83)
Zhang et
al
2016(86)
Wagner
et al
2016(66)

Control (61:22) vs.
metabolic syndrome
(32:12)
16 patients diagnosed with
IgA nephropathy (IgAN)
compared to 12 controls
Patients with symptoms
requiring heart
catheterization to
diagnosis obstructive CAD
(52:48)

CTRP3 levels were lower in women with PCOS (200 ng/ml)
compared with control (330 ng/ml); Metformin intervention
increased CTRP3 levels to (272 ng/ml). BMI, Insulin, LDL,
Triglycerides, CRP and Carotid intima-media thickness were all
negatively associated with CTRP3 levels. TNF levels were not
associated with CTRP3
CTRP3 was inversely associated with BMI and triglyceride levels.
Men had significantly lower CTRP3 levels compared to women
(397.7 vs. 432 ng/mL, p<0.01).
CTRP3 concentrations exhibit a significant negative association
with cardiometabolic risk factors and positive association with
adiponectin.
CTRP3 levels were lower in patients with IgAN (TGF-β and IL-6
levels were elevated in these patients).
No association between obstructive coronary artery disease and
CTRP3 levels. CTRP3 levels were higher in lean female than
males. CTRP3 levels increased with obesity in males, but decreased
with obesity in female patients.

Human studies
To date very few experimental intervention studies have been performed with
human subjects. The first, Wurm et al. (2007) (78) examined circulating CTRP3 levels
before and 2 hours after a glucose load (n=20, 14 males and 6 females) and observed
no change. However, this study occurred before there were reliable ELISA’s developed
for CTRP3 and examined CTRP3 levels solely though immunoblot analysis. Further
complicating the results from this study is that although they reported the supplier (R&D
Systems) they did not include the catalog number for the antibody used and they
reported band migration of 50 kDa for CTRP3 on a denaturing SDS-PAGE. CTRP3 has
a predicted and gel migration ~30 kDa and although the posttranslational modifications
for CTRP3 could result in a higher than predicted migration pattern on an SDS gel, this
has not been observed by other researchers (1, 43, 51, 70, 75). Indeed, the antibody for
human CTRP3 from R&D Systems (R and D Systems Cat# AF7925,
RRID:AB_2619735) also reports detecting a band at ~30 kDa. Moreover, using an
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ELISA based method Ban et al. (2014) observed that in type 2 diabetic patients CTRP3
levels decreased from ~150 to 50 ng/ml in response to a 2-hour oral glucose load (5). In
light of these data and the progress within the past 9 years in CTRP3 antibody and
ELISA development, the effects of glucose on CTRP3 levels in a healthy human subject
population should be reexamined. In addition, due to the potential role of CTRP3 in lipid
metabolism, experiments should also examine the effects of acute lipid loading
on circulating CTRP3 levels.
Only one study has examined the effects of exercise on circulating CTRP3
levels in human subjects. Briefly, Choi et al. (2013) examine changes to circulating
CTRP3 levels after a 3-month exercise program (45 min cardio/20 min resistance
5x/week) in 76 obese Korean females. (10) They found that CTRP3 levels decreased by
~15% (444 ng/ml to 374 ng/ml) after exercise intervention. The exercise training
program also resulted in ~9% loss in body weight, so it is unclear if the change in
CTRP3 levels were due to exercise or the reduction in body fat. The effects of acute
exercise or exercise training on CTRP3 levels in a healthy human population or in the
absence of weight loss have not been investigated.
Lastly, Tan et al. (2013) (65) reported that women with polycystic ovary
syndrome had lower levels of CTRP3 than control subjects. Polycystic ovary syndrome
is an endocrine system disorder associated with obesity, diabetes, dyslipidemia, and
cardiovascular complications and Metformin is a common medication used in the
treatment of insulin resistance, obesity and type 2 diabetes. CTRP3 levels were
restored with Metformin treatment along with general improvement in insulin sensitivity.

56

CTRP3 and Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death in the world,
accounting for 30% of all deaths. (17) The identification of novel biomarkers indicating
the progression, or signaling pathways which can be exploited as a treatment, for CVD
is an ongoing interest for combating this disease. It is well established that obesity is a
leading risk factor for CVD (63), however very little attention has been given to the
endocrine function of adipose tissue and its role in CVD. In both cell culture and animal
models CTRP3 has been shown to be protective following heart attack (myocardial
infarction, MI) or stroke (intracerebral hemorrhage, ICH) (11, 42, 67, 77, 80, 81, 83, 89).
Table 3.6 contains the complete summary of the treatment effects of CTRP3 treatment
as it related to CVD. Specifically, CTRP3 stimulates mitochondrial biogenesis in cardiac
tissue and promotes vascular relaxation (85,89), whereas immediately following an MI
there is a significant decrease of adipose tissue CTRP3 mRNA and circulating CTRP3
protein levels (77, 81). In animal models of MI exogenous CTRP3 pretreatment
(adenovirus-delivered or recombinant CTRP3) increases survival, improves postevent
cardiac function, and prevents pathological remodeling (77, 81). Progressive remodeling
after myocardial infarction (MI) is a leading cause of morbidity and mortality associated
with MI. Specifically Transforming growth factor beta (TGF-β) has been reported to be
involved in ventricular remodeling by promoting myocardial fibrosis (88). However,
CTRP3 attenuates TGF-β1-induced signaling and pathogenic remodeling post-MI both
in vivo and in vitro (77). Regarding stroke recovery, preconditioning with CTRP3
reduced cerebral edema, reduced blood-brain barrier damage, improved neurological
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function, and reduced oxidative stress following ICH (67,80). Collectively, these data
illustrate the potential of CTRP3 and CTRP3-mediated signaling pathways as a
prospective post-MI/ICH treatment targets.
Table 3.6: Summary of Cardiovascular Effects of CTRP3 Treatment
Model

Treatment/Measurement

Effect

MSS31 (mouse
endothelial
cells(79))

Referenc
e
Akiyama
(2) et al
(2007)

1-5 µg/ml [E. Coli produced
His6-tagged signal peptide
removed]

↑ Proliferation and migration, ↑ ERK1/2 &
MAPK p38 within 15 minutes.

Rat vascular
smooth muscle
cells (VSMCs)

Feng et
al
2016(15)

Recombinant human
globular CTRP3 (Aviscera
Bioscience, no catalog #
provided), or siRNA
knockdown of CTRP3

CTRP3 increase ATP synthesis and oxidative
phosphorylation complex proteins, reversed
with knockdown. CTRP3 increases
mitochondrial ROS.

Rat vascular
smooth muscle
cells (VSMCs)

Feng et
al
2016(15)

Recombinant human
globular domain CTRP3
(Aviscera Bioscience, no
catalog # provided)

CTRP3 increases mitochondrial Reactive
oxygen species levels in VSMC.

Adventitial
fibroblasts

Lin et al
2014(42)

CTRP3 protein (10 µg/ml)
(source/type of CTRP3 was
not reported)

CTRP3 prevents TGF-β1 induced fibroblasts
phenotypic conversion, proliferation,
migration, and collagen I expression.

Primary
cultured adult
rat cardiac
fibroblast (CF)

Wu et al
2015(77)

2 µg/ml Recombinant
human gCTRP3 (Aviscera
Bioscience; 00082-01-100;
E. Coli expressed); also
used siRNA knockdown of
CTRP3

CTRP3 inhibited TGF-β1 induced markers for
myofibroblast differentiation and TGF-β1
induced- phosphorylation of Smad3. Whereas,
CTRP3 knockdown increased TGF-β1
induced markers for myofibroblast
differentiation.

Rat
intracerebral
hemorrhage
(ICH)

Yang et
al
2016(80)

+/- lentivirus or
recombinant CTRP3 (80
µg/kg, Chimerigen, USA),

Reduced cerebral edema and blood-brain
barrier damage and improved neurological
functions and reduced oxidative stress via
PKA signaling pathway

Cardiomyocyte
s (adult mouse)

Yi et al
2012(81)

Bacterial expressed globular
domain of Mouse CTRP3,
and condition media from
3T3-L1a cell +/- CTRP3
siRNA.

CTRP3 upregulated levels of phosphorylated
Akt, HIF1α, and VEGF. Cardiomyocyte
hypoxia-induced apoptosis was attenuated
with condition media from 3t3-L1A
adipocytes, abolished with CTRP3 siRNA.

HUVEC

Yi et al
2012(81)

Bacterial expressed globular
domain of mouse CTRP3

Condition media from primary
cardiomyocytes treated with CTRP3
significantly enhanced HUVEC tube
formation. No direct effect of CTRP3

Mouse myocardial
infarction (MI)

Yi et al
2012(81)

Adenovirus or bacterial
expressed globular domain
of mouse CTRP3

MI reduced CTRP3 levels, CTRP3 treatment
improved survival rate, restored cardiac
function, increased revascularization, and
reduced fibrosis
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Neonatal rat
ventricular
myocytes

Zhang et
al
2016(85)

0.5 – 4 µg/ml Human
recombinant globular and
full-length CTRP3
(Aviscera Bioscience, no
catalog #)

CTRP3 increased AMPK activated
transcription factors and restored hypoxiareoxygenation injury induced reduction in
sirtuin1, PGC-1α, NRF-1, complex III and
ATP content.

Aortic rings
from C57BL/6
mice

Zheng et
al
2011(89)

mammalian expressed
CTRP3 (1, 3, & 10 µg/ml)

3 and 10 (but not 1) µg/ml of mammalian
expressed CTRP3 caused significant
vasorelaxation.

Rat Cultured
Carotid
Arterial Rings

Zhou et
al
2014(90)

(1-4 µg/mL) human
globular CTRP3 (Aviscera
Bioscience, 00082-01-100)

CTRP3 Promotes Vascular Calcification in
High-Phosphate Cultured Carotid Arterial
Rings.

Rat vascular
smooth muscle
cells (VSMCs)

Zhou et
al
2014(90)

(1-4 µg/mL) human
globular CTRP3 (Aviscera
Bioscience, 00082-01-100)

CTRP3 Promotes β-Glycerophosphate–
Induced VSMC Calcification and
mitochondrial Reactive oxygen species levels
in VSMC.

Mouse:
Adenineinduced
chronic renal
failure (CRF)

Zhou et
al
2014(90)

CTRP3 levels measured by
ELISA and RT-qPCR or
Adenovirus encoding fulllength human CTRP3

Protein CTRP3 levels increased but adipose
mRNA expression was reduced with CRF.
CTRP3 Increased Vascular Calcification.

CTRP3 is also demonstrated to play a large role in angiogenesis and
endothelial cell proliferation. (2, 23, 45, 81) For example, during the recovery period
following rat carotid artery balloon-injury model CTRP3 expression increases
dramatically (35). Interestingly CTRP3 may not act directly on the endothelial cells, but
through indirect pathways mediated by cardiac or smooth muscles cells. Direct
treatment of Human Umbilical Vein Endothelial Cells (HUVEC) with CTRP3 had no
direct effect on capillary-like structures formation (tube formation), Akt phosphorylation
or hypoxia-inducible factor 1, alpha subunit (HIF-1α) or Vascular endothelial growth
factor (VEGF) expression. (81) However, conditioned media from primary
cardiomyocytes treated with CTRP3 induced HUVEC tube formation, indicating the
presence of CTRP3-induced cardiomyocyte-secreted paracrine factors. (81) However,
the direct effect of CTRP3 on HUVEC cells cannot be completed ruled out as Yi et al.
(2012) (81) used bacterial expressed CTRP3 directly on HUVEC cells and used
mammalian expressed CTRP3 in vivo. This discrepancy may indicate a post59

translational modification is required for CTRP3-induced effects on vascular
endothelium.
As shown in table 3.6, very few studies have examined the association between
CVD and circulating CTRP3 levels in a human patient population. Specifically, Wagner
et al. (66) observed no association between the presence of CVD and CTRP3 levels
among patients with symptoms requiring catherization for detecting the presence of
coronary artery blockage. Whereas, Deng et al. 2015 (14), observed that both obesity
and high blood pressure were associated with lower CTRP3 levels and Choi et al. 2014
(11) reported that CTRP-3 concentrations in patients with acute coronary syndrome or
stable angina pectoris were significantly decreased compared to control subjects.
Further, CTRP3 concentrations have been shown to exhibit a significant negative
association with many cardiometabolic risk factors (11, 83). As CTRP3 levels decrease
with obesity, at least in men (66), the lower levels of CTRP3 may contribute to the
impaired mitochondrial biogenesis in cardiac cells and increase the
susceptibility/severity of an MI event. On the other hand, excessive sustained elevation
of CTRP3 may also be detrimental to cardiovascular health as CTRP3 as promotes
vascular and aortic ring calcification (90), increase vascular calcification promotes
arterial hardening and the development of arteriosclerosis. Regardless of the
associations between CTRP3-mediated signaling and CVD appear promising and need
to be investigated in more detail.
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Inflammation
Metabolic syndrome is defined as a cluster of risk factors which directly
increase the risk of CVD, T2D, and all-cause mortality (4, 26). One of the major defining
risk factors for metabolic syndrome is a chronic state of low-grade inflammation state
marked by elevated circulating pro-inflammatory cytokines (TNF, IL-6, and C-reactive
protein). The adipose tissue immune response plays a major role in the development of
the chronic pro-inflammatory state (22, 26). Whereas, CTRP3 is a potential antiinflammatory mediator, and is negatively associated with the pro-inflammatory cytokines
TNF, IL-6, and C-reactive protein (5, 11, 12, 14, 48, 50, 52, 65, 83). In animal models
diet-induced obesity results in decreased CTRP3 levels concurrent with an elevation in
TNF and IL-6 (50). Similarly, diet-induced obese CTRP3-knockout mice have an
enhanced elevation of IL-6 and TNF levels (71). Further, transgenic overexpression of
CTRP3 attenuates the high-fat diet induce rise in cytokine levels and more than doubles
circulating soluble gp130 (sgp130) levels (50). Circulating sgp130 is a potent inhibitor of
inflammatory cytokines such as IL-6 (24). On another note, although essential for
regulating platelet aggregation, excessive levels of the cytokine thromboxane A2 are
associated with the development of insulin resistance and arteriosclerosis (18), and are
elevated in both human and mouse models of obesity (33). However, loss of
Thromboxane synthase (TBXAS), the enzyme necessary to produce thromboxane A2,
markedly enhances insulin sensitivity concurrent with the up-regulation of CTRP3, as
well as other adipokines (CTRP9, CTRP12) (33). CTRP3 has also demonstrated
potential as a treatment for a specific inflammatory disorder, IgA nephropathy (IgAN).
IgAN is a kidney disorder caused by deposits of the protein immunoglobulin A (IgA)

61

inside the glomeruli of kidney and excessive mesangial cell activation. In patients with
IgAN CTRP3 levels are significantly reduced and the cytokines IL-6 and TGF-β are
elevated (86). Treatment of isolated adult human mesangial cells (HMCs) with CTRP3
reduced IL-6 and TGF-β production and inhibited HMC activation (86). Combined these
data demonstrate the potential of CTRP3 in the treatment of inflammatory disorders.
The summary finding of all studies examining the connection between inflammation and
CTRP3 are listed in Table 3.7.
Table 3.7: CTRP3 and Inflammation
Model

Referen
ce
Hofman
n et al
2011(21
)

Type of treatment

Effect

Recombinant CTRP-3
(High Five insect
cells)

Significantly and dose-dependently reduced
LPS-induced IL-8 secretion in CLPF within
8 hours after LPS exposure, whereas LPSinduced IL-6 and TNF release was not
affected. CTRP-3 inhibited TGF-β
production and the expression of CTGF and
collagen I in CLPF, whereas collagen III
expression remained unchanged.

Primary Human
monocytes

Kopp et
al
2010(30
)

1 µg/ml Recombinant
full length CTRP3
(H5 insect cells)

Suppressed LPS-induced MIF & CCL4
release in lean subjects, & MCP-1 in
monocytes from both diabetic and leans
subjects. Prevents Lauric acid induced
release of IL-6 and TNF

Primary Human
monocytes

Kopp et
al
2010(31
)

1 µg/ml Recombinant
full length CTRP3
(H5 insect cells)

↓ LPS-induced secretion of IL-6 in
monocytes from control but not T2D.
CTRP3 did not significantly affect TNF
secretion.

Adipocyte
(3T3-L1)

Li et al
2014(38
)

Recombinant CTRP3
(uncited origin)

Decreased TNF and IL6 secretion in insulin
resistant 3T3-L1A.

Transgenic
CTRP3
overexpression
and CTRP3
Knockout

Peterse
n et al
2016
(48)

Response to sublethal
dose of LPS challenge

No effect on IL-1β, IL-6, TNF-α, or MIP-2
induction.

LPS (1 µg i.p.)
into male mice
+/- CTRP3

Schmid
et al.
2014
(60)

Recombinant CTRP-3
(H5 insect cells)

Intraperitoneal injection (but not IV)
injection of CTRP-3 significantly reduced
LPS-induced IL-6 and levels MIP-2.

Human primary
colonic lamina
propria
fibroblasts
(CLPF)
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16 patients
diagnosed with
IgA
nephropathy
(IgAN)
compared to 12
controls

Zhang
et al
2016
(86)

THP-1 (human
- Acute
Monocytic
Leukemia cell
line)

Weigert
et al
2005
(70)

CTRP3 levels were lower in patients with
IgAN (TGF-B and IL-6 levels were elevated
in the patients).

1 µg/ml Recombinant
full length CTRP3
(H5 insect cells)

Suppressed LPS induced: IL-6 & TNF
expression and secretion.

Lipopolysaccharide (LPS), is a well-established endotoxin used as a model of
systemic immune response, in vivo. In cell culture models LPS inhibits adipose tissue
differentiation, induces insulin resistance, and prevents the expression of CTRP3 (59).
Whereas, CTRP3 has been shown to specifically block the binding of LPS to its
receptor TLR4 (13, 30) and inhibit the inflammatory response (30). Further, in animal
models intraperitoneal injection (IP) injection of CTRP3 (0.4ug/g body weight)
significantly reduced LPS-induced (IP) inflammatory response (65). Although
intravenous administration of CTRP3 was unable to prevent LPS-induced inflammation,
this is thought to be a dose related limitation and future studies are ongoing to
determine the clinically relevant levels of CTRP3 administration needed to inhibit a
systematic immune response. Further, CTRP-3 potently inhibited LPS-induced IL-6 in
monocytes isolated from healthy subjects but not in monocytes derived from a subject
with T2D (31, 70). Similarly, the anti-inflammatory effects of CTRP3 have also been
observed in isolated primary human colonic fibroblasts (21). Combined, these data
show promise for the use of CTRP3 and CTRP3-mediated pathways as a potential antiinflammatory mediator. However, neither chronic CTRP3 deficiency nor overexpression
altered the inflammatory response to a sublethal challenge to LPS (48), indicating that
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CTRP3 levels need to be regulated transiently to demonstrate an anti-inflammatory
effect. Regardless, the potential use of CTRP3 as an inhibitor of inflammation needs to
be examined in more detail.
Growth, Reproduction, and Tumorigenesis
CTRP3 has been linked to normal and pathogenic cellular proliferation, growth
and development. CTRP3 has been consistently shown to stimulate the proliferation of
chondrogenic precursors, chondrocytes, and osteocytes, in vitro, through activation of
ERK1/2 and PI3K pathways (1, 3, 27, 44, 82). During early development CTRP3 is
detected in developing chondrocytes (43) and cartilage (44) which has led to the
hypothesis that CTRP3 is essential for normal cartilage and bone development. In
support of this CTRP3 is appears to be essential for proper mandible formation through
perichondrium maintenance and new cartilage formation (82). However, the role of
CTRP in development may be dispensatory as CTRP3-knockout animals do not
demonstrate a growth phenotype indicating a possible compensatory mechanism during
development. However, CTRP3-knockout mice do exhibit increased susceptibility to
collagen-induced arthritis, indicating CTRP3 may be important for the maintenance and
repair of cartilage tissue (46). However, elevated CTRP3 may also be detrimental as
CTRP3 is highly secreted from and increases growth rates of osteosarcoma and
chondroblastoma tumor cell lines indicating that CTRP3 may be linked to these types of
cancers (54). However, no cancers have been reported in CTRP3 transgenic
overexpressing mice, although this has not been specifically examined. Lastly, CTRP3
is specifically expressed in the testosterone producing interstitial Leydig cells and
treatment of TM3 mouse Leydig cells with CTRP3 increased testosterone production
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(47). Although these findings may shed some light on the discrepancy between male
and female in circulating CTRP3 levels, the overall clinical significance has yet to be
explored.
SUMMARY AND CONCLUSION
Adipose tissue secretes numerous adipokines that contribute to a wide array of
biological processes. CTRP3, is a novel and unique member of the adipokine
superfamily which appears to have unique roles in a variety of tissue: hepatic lipid
metabolism, cardiovascular response to ischemia, and increases chondrocyte
proliferation and differentiation. CTRP3 can function in an autocrine, paracrine, and
endocrine manner and there are many aspects of CTRP3’s regulation and function that
have yet to be explored. In addition, CTRP3 has been consistently linked to activation of
the PKA signaling pathway, regardless of the tissue/treatment paradigm examined (37,
47, 80). This review should serve as a basis for the design of future experimental
studies specifically examining: (i) the regulation of CTRP3 in response to food intake or
exercise, (ii) associations between circulating CTRP3 levels, including the two different
splice variants (CTRP3A and CTRP3B), and hepatic steatosis or osteoscarcoma in
clinical population, and (iii) the associations between the different CTRP3 isoforms
(CTRP3A and CTRP3B) and multimeric structures in clinical populations, (iv) the
potential use of CTRP3 as an inhibitor of inflammation, and (v) whether the putative
receptors, LAMP-1 and LIMPII are directly responsible for the intracellular effects
of CTRP3 or at as co-receptors for a yet unidentified protein. Finally, the gender-specific
regulation of CTRP3 needs to be explored in more detail (splice variants and multimeric
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structures) especially in regards to the association between CTRP3 and human
diseases such as non-alcoholic fatty liver disease, T2D, and metabolic syndrome.
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IDENTIFICATION OF PUTATIVE RECEPTORS FOR THE NOVEL ADIPOKINE
CTRP3 USING LIGAND-RECEPTOR CAPTURE TECHNOLOGY
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ABSTRACT
C1q/TNF Related Protein 3 (CTRP3) is a member of a family of secreted proteins that
exert a multitude of biological effects. Our initial work identified CTRP3’s promise as an
effective treatment for Nonalcoholic fatty liver disease (NAFLD). Specifically, we
demonstrated that mice fed a high fat diet failed to develop NAFLD when treated with
CTRP3. The purpose of this current project is to identify putative receptors which
mediate the hepatic actions of CTRP3. We used Ligand-receptor glycocapture
technology with TriCEPS™-based ligand-receptor capture (LRC-TriCEPS; Dualsystems
Biotech AG). The LRC-TriCEPS experiment with CTRP3-FLAG protein as ligand and
insulin as a control ligand was performed on the H4IIE rat hepatoma cell line. Initial
analysis demonstrated efficient coupling of TriCEPS to CTRP3. Further, flow cytometry
analysis (FACS) demonstrated successful oxidation and crosslinking of CTRP3TriCEPS and Insulin-TriCEPS complexes to cell surface glycans. Demonstrating the
utility of TriCEPS under these conditions, the insulin receptor was identified in the
control dataset. In the CTRP3 treated cells a total enrichment of 261 peptides was
observed. From these experiments 5 putative receptors for CTRP3 were identified with
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two reaching statistical significance: Lysosomal-associated membrane protein 1 (LAMP1) and Lysosome membrane protein 2 (LIMP II). Follow-up Co-immunoprecipitation
analysis confirmed the association between LAMP1 and CTRP3 and further testing
using a polyclonal antibody to block potential binding sites of LAMP1 prevented CTRP3
binding to the cells. The LRC-TriCEPS methodology was successful in identifying
potential novel receptors for CTRP3. The identification of the receptors for CTRP3 is an
important prerequisites for the development of small molecule drug candidates, of which
none currently exist, for the treatment NAFLD.
INTRODUCTION
Since the discovery of leptin by Zhang et al. (1) many secreted bioactive
molecules have been identified which originate from adipose tissue. Thus far, over 260
unique adipose tissue derived secreted proteins/peptides have been identified,
collectively termed adipokines (2-5). Efforts to identify such metabolic regulators have
led to the discovery of a family of secreted proteins, designated as C1q/TNF-Related
Proteins, with 15 unique proteins currently identified (CTRP1-15) (6-14). C1q family
proteins are characterized by a distinctive ‘globular domain’ of about 140 amino acids
(the gC1q domain) (14). The CTRP proteins, adiponectin, TNF-alpha, as well as other
proteins with the C1q domain are collectively referred to as the C1q/TNF superfamily
(14-18). Proteins within the C1q/TNF superfamily share some structural similarities, but
may have apposing functions (18). To date, many unique functions have been identified
for the CTRP proteins encompassing regulatory roles in metabolism, inflammation and
cell proliferation (6, 9, 15-29). Of these proteins our lab has identified a liver specific role
for CTRP3 in preventing Nonalcoholic fatty liver disease (NAFLD) (29).
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Adiponectin, the most widely studied member of the C1q/TNF superfamily, increases
lipid oxidation in liver and skeletal muscle (16, 30-32). Unlike adiponectin or other C1q
TNF related proteins, we observed no direct effect of CTRP3 on skeletal muscle in
vitro or in vivo (9, 29). This implies that CTRP3 works through a novel receptor, as the
three identified receptors for adiponectin are all present in skeletal muscle (33-35). In
further support of this hypothesis both CTRP3 and adiponectin decrease hepatic TAG
accumulation, however adiponectin reduces hepatic triglyceride levels largely through
activation of AMP-activated protein kinase (AMPK) pathways (32), whereas CTRP3 did
not affect AMPK phosphorylation status (9, 29). The finding of divergent downstream
signaling pathways also argues that CTRP3 has a receptor distinct from adiponectin.
Combined, these data indicate that CTRP3 is a distinct member of the C1q/TNF
superfamily and functions through a unique receptor in liver. The receptor and the
mechanism(s) responsible for the CTRP3-induced reduction in hepatic TAG
accumulation remain unexplored.
LRC-TriCEPS™ is promising, novel technology recently described in Nature
Protocols and Nature Biotechnology (36, 37). First published by the lab of Bernd
Wollscheid, TriCEPS™ is a chemoproteomic reagent coupled to a ligand of interest
(CTRP3) that acts to covalently link the ligand to the cell-based receptor (36). This
linkage protects the ligand-receptor conjugate from the subsequent digestion steps and
peptide level purification via the biotin tag on the TriCEPS™ molecule. The TriCEPS™
and the ligand are subsequently released through specific enzymatic cleavage and the
receptor peptides are collected and analyzed by Liquid chromatography-tandem mass
spectrometry (LC-MS/MS). The LRC-TriCEPS™ technique has been validated through
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successful detection of known receptors, however, using this technology to identify
receptors for novel proteins is still in its infancy (36, 37).
The purpose of this study was to determine if we could successful use the LRCTriCEPS™ to identify novel potential receptors which mediate the hepatic effects of
CTRP3. In brief, we were able to identify five potential novel receptors using the LRCTriCEPS™ technique.
EXPERIMENTAL PROCEDURES
Cell culture. HEK-293T cells (Thermo fisher, GripTite 293 MSR Cell Line Cat #
R79507) were cultured in Dulbecco's Modification of Eagle's Medium (DMEM) with 4.5
g/L glucose without L-glutamine and sodium pyruvate (Corning, Cat# 15-017)
supplemented with 5% (v/v) fetal bovine serum (HyCloneTM, Cat# SH30088.03) and
with antibiotic/antimycotic Solution (Corning, Cat# 30-004-CI). HEK-293T cells were
used for transfection and protein purification protocols. H4IIE cells (H-4-II-E rat
hepatoma cells, ATCC® cat# CRL-1548™, RRID:CVCL_0284) were cultured in DMEM
containing 1 g/L glucose, L-glutamine, and sodium pyruvate (Corning Cat# 10-014)
supplemented with 10% (v/v) fetal bovine serum (HyCloneTM, cat# SH30088.03) and
with antibiotic/antimycotic Solution (Corning, Cat# 30-004-CI). H4IIE rat hepatoma cells
are a well-established in vitro model of hepatocytes, useful for metabolic research as
this cell line mirrors the liver-like, insulin regulated glucose and lipid metabolism found in
the liver (38-40). Further, the CTRP3 amino acid sequence is highly conserved
throughout vertebrate evolution with only 4 amino acids differing between the mouse
and rat orthologs and a 95% homogeneity between mouse and human (6, 9). Therefore,
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we expect that the receptor and metabolic effects of CTRP3 established in H4IIE cell
line in vitro will provide insight to the actions of CTRP3 in vivo.
Protein purification. C-terminal FLAG-Tagged mouse CTRP3 and CTRP1 were
produced as described previously (9, 41). Briefly, transient transfections were
performed on HEK-293T cells using calcium phosphate according to standard protocols
(42). At 48 h after transfection, cells were washed and then cultured in serum-free OptiMEM I medium (Invitrogen, Cat# 51985034) supplemented with vitamin C (0.1 mg/ml;
Fisher Scientific Company, Cat# FLBP351). Supernatants were collected three times,
every 48 h, pooled and purified using an anti-FLAG affinity gel according to the
manufacturer's protocol (Biotool.com, Cat# B23101), and eluted with 150 μg/ml FLAG
peptide (Sigma, Cat# F4799). Dialysis was performed on purified proteins with 20 mM
Hepes buffer (pH 8.0) containing 135 mM NaCl in a 10 kDa cut-off Slide-A-Lyzer
dialysis cassette (Thermo Fisher Scientific, Cat# 88252).
Immunofluorescence. For visualization H4IIE hepatocytes were grown to
confluence on Millicell EZ SLIDE (Millipore Cat# PEZGS0816) in standard growth
medium. The cells treated with recombinant FLAG tagged CTRP3, CTRP1, or vehicle
for 1 hr. Afterwards the cells were washed in phosphate buffered saline (PBS; 137 mM
NaCl, 10 mM Phosphate, 2.7 mM KCl, ph 7.2) fixed in 4% formaldehyde diluted in PBS
for 10 minutes at 37°C, washed with PBS, and then blocked in 5% Normal goat serum
(diluted in PBS). The cells were then incubated with rabbit anti-FLAG (Cell Signaling
Technology Cat# 14793; RRID: AB_2572291) followed by fluorochrome-conjugated
secondary antibody (Cell Signaling Technology Cat# 4412 RRID: AB_1904025). Cells
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were then mounted with an anti-fade mounting medium with DAPI (DAPI FluoromountG®; SouthernBiotech Cat# 0100-20), and immunofluorescence was visualized [Zeiss
Observer.Z1].
Fatty acid oxidation. H4IIE hepatocytes were allowed to adhere to 24-well
culture plates XF24 cell culture microplate (Seahorse Bioscience, Cat# 100777-004)
after seeding for 2 days, according to standard protocols (Seahorse Bioscience). Cells
were pre-incubated with 5 µg/ml CTRP3 or vehicle for 1 H then transferred into XF
assay medium (Seahorse Bioscience, Cat# 100965-000) supplemented with 0.5mM
sodium pyruvate and 5mM glucose before being placed into the XF24 Extracellular Flux
Analyzer (Seahorse Bioscience XF24). The dosage of recombinant CTRP3 was
selected based on our previous experimental observations (9), and is well within the
common dosages reported within the literature of 2-30 µg/ml (9, 29, 43, 44). Sensor
cartridge of XF24 extracellular flux assay kit (Seahorse Bioscience, Cat# 100850-001) is
hydrated by loading 1ml XF calibrant (Seahorse Bioscience, Cat# 100840-000) into
each well in utility plate and incubating at 37°C overnight in a non-CO2 incubator. 200
uM palmitate conjugated to bovine serum albumin (BSA) or fatty acid free BSA (served
as a vehicle control) was added in XF24 cell culture microplate at time-points indicated.
A 1 mM working stock of palmitate (Sigma Cat# P5585) conjugated to 0.17 mM fatty
acid free BSA (Sigma Cat# A8806) was prepared according to established protocols
(Seahorse Bioscience). Briefly, 50 ml of a BSA solution (0.34 mM BSA, 150 mM NaCl,
pH 7.4) was heated to 37°C and 40 ml of a palmitate solution (2.98 mM palmitate, 150
mM NaCL), heated to 70°C, and was added in 5 mL increments. The combined
solution was incubated at 37°C for 1 H under constant agitation, afterwards the pH was
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adjusted to 7.4 and the final volume was adjusted to 100 mL with 150 mM NaCl.
Aliquots were stored until use at -20°C in glass vials.
Flow Cytometry. H4IIE hepatocytes were grown to confluence in 6-well plates
(Corning Costar® Cat# 3516) and then treated with/without recombinant CTRP3-FLAG
for indicated times. The cells were then collected in PBS, fixed in 4% formaldehyde, and
then incubated with rabbit anti-FLAG antibody (Cell Signaling Technology, Cat# 14793;
RRID: AB_2572291) followed by fluorochrome-conjugated secondary antibody (Cell
Signaling Technology, Cat# 4412; RRID:AB_1904025). Next cells were suspended in
buffer (0.5% Bovine Serum Albumin in PBS) and analyzed for mean fluorescent
intensity (MFI) by using a FACScalibur flow cytometer with (CellQuest software, BD
Biosciences). Except for the quality control step for LRC-TriCEPS (see below), all FACS
experiments were performed three separate times in triplicate for each experiment. For
blocking experiments cells were co-incubated with polyclonal Lysosomal-associated
membrane protein 1 (LAMP-1) antibody (Santa Cruz Biotechnology Cat# sc-8098,
RRID:AB_2134494)
TriCEPS™-based ligand-receptor capture (LRC-TriCEPS). In conjunction with
Dualsystems Biotech AG, TriCEPS™-based ligand-receptor capture (LRC-TriCEPS;
Dualsystems Biotech, cat# P05201) was utilized to identify the putative receptor for
CTRP3 according to manufacturers directions. Briefly, 300 µg recombinant CTRP3FLAG protein or Insulin (control ligand) was dissolved in 150 µl HEPES buffer (25 mM,
pH 8.2) and 1.5 μl of the TriCEPS™ reagent was added to each sample and incubated
for 2 H at 20°C under constant gentle agitation. After incubation 1µl of each sample was
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removed to complete a Dot blot experiment as a quality control to test for efficient
TriCEPS™ coupling to the ligands (data not shown). Three separate 50 mL tubes each
containing 2x108 H4IIE Hepatocytes in PBS (pH 6.5) were washed and cooled to 4°C,
all subsequent steps were performed at 4°C. 200 μl was collected from each tube and
labeled as non-oxidized cells. Next, to mildly oxidize the cell surface proteins 1.5 mM
NaIO4 was added to each tube and cells were incubated at 4°C in the dark for 15 min
under gentle rotation. The cells were then washed twice at 300 x g for 5 min and then
resuspended in 20 ml PBS (pH 6.5). An aliquot of ~80 μl was collected from each tube
and labeled as oxidized cells. The cells were then evenly divided into 6 separate tubes
and 50 µl of either TriCEPS™-coupled insulin or TriCEPS™-coupled CTRP3 was added
to each tube and incubated for 90 min at 4°C under constant gentle agitation. An aliquot
of ~80 µl was collected from each tube and the collected samples (non-oxidized cells,
oxidized cells, insulin cells and CTRP3-FLAG cells) were analyzed by FACS to test for
the crosslinking efficiency of the TriCEPS™-ligand complexes to the cell surface
glycans using fluorochrome conjugated streptavidin (Thermo Fisher Scientific Inc.
eBioscience Cat# 11-4317). After completion of the coupling reaction, the cells were
collected and the cell pellet was sent to Dualsystems for LC-MS/MS analysis.
LC-MS/MS analysis. The samples were analyzed on a Thermo LTQ Orbitrap XL
spectrometer fitted with an electrospray ion source. The samples were measured in
data dependent acquisition mode in a 60 min gradient using a 10cm C18. The six
individual samples in the dataset were analyzed with a statistical ANOVA model. This
model assumes that the measurement error follows Gaussian distribution and views
individual features as replicates of a protein's abundance and explicitly accounts for this
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redundancy. It tests each protein for differential abundance in all pairwise comparisons
of ligand and control samples and reports the p-values. Next, p-values are adjusted for
multiple comparisons to control the experiment-wide false discovery rate (FDR). The
adjusted p-value obtained for every protein is plotted against the magnitude of the fold
enrichment between the two experimental conditions. Proteins are considered
significant if FC>2 and adj. p-value<0.05.
Co-Immnunoprecipitation (Co-IP) and Immunoblot Analysis. H4IIE hepatocytes
were grown to confluence in 6-well plates (Corning Costar® Cat# 3516) and then
treated overnight with/without recombinant CTRP3-FLAG overnight. The cells were
then washed with PBS and collected in Non-denaturing lysis buffer (20 mM Tris HCl pH
8, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM EDTA). Cells were incubated
with constant agitation for 30 minutes at 37°C and then centrifuged at 10,000xg at 4°C
for 10 minutes and the supernatant was collected and protein concentration was
determined via Bradford assay (Pierce Coomassie Plus Cat# 23238). Equal amounts of
protein were diluted to 500 µl final volume and used for immunoprecipitation according
to manufactures directions (Bimake, Anti-DYKDDDDK(Flag) Affinity Gel Cat# B23101).
Total protein homogenate or immunoprecipitate were loaded and separated on a 12%
Mini-Protean® TGXTM gel (Bio-Rad, Cat#456-1046) and transferred to nitrocellulose
membranes (0.45 μm, Bio-Rad Cat#1620115). Membranes were blocked in 2% non-fat
milk and probed with primary antibodies overnight at 4°C (Anti-LAMP1, Abcam Cat#
ab24170, RRID:AB_775978; or Anti-LIMPII, Abcam Cat# ab176317, RRID:
AB_2620169) followed horseradish peroxidase (HRP)-conjugated goat anti-rabbit
secondary antibody (Thermo Fisher Scientific Cat# 31460, RRID:AB_228341).
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Membranes were incubated with HRP Substrate (Millipore Immobilon Cat#
WBKLS0100) and chemiluminescence was then visualized with FuorChem® M imager
(ProteinSimple). Precision Plus Protein™ Dual Color Standards molecular weight
markers were used in all immunoblot analysis (BioRad Cat#161-0374).
Statistical Analysis. For analysis of flow cytometry and fatty acid oxidation, data
from each experiment were normalized to the control and the combined data from the
three independent replicates was combined and analyzed with a one-way ANOVA (flow
cytometry) or repeated measure ANOVA (fatty acid oxidation) followed by Tukey's
multiple comparisons test Post hoc analysis. Statistics analysis were completed by
Graphpad Prizm version 6.
RESULTS
CTRP3 binds and has a physiological effect on hepatoma cells
Immunohistochemical analysis was used to demonstrate that recombinant
CTRP3, but not CTRP1 binds to H4IIE hepatocytes in vitro (Figure 4.1). Confirmatory
experiments using flow cytometry demonstrated a 200% increase in mean fluorescent
intensity (MFI) when cells were treated with recombinant FLAG tagged CTRP3 and
probed with anti-FLAG antibodies, compared with vehicle, and fluorochrome-conjugated
secondary antibody alone treatments (Figure 4.2C). Interestingly, only a subset (~20%)
of H4IIE cells stained positive for CTRP3 binding. This may indicate that CTRP3
receptor surface expression is transient. For instance, it may be yoked to the cell cycle
or some other parameter of cellular circumstance.
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Figure 4.1: CTRP3 Binds to Hepatocytes In Vitro. H4IIE hepatocytes were plated on Millicell EZ
SLIDE (Millipore) and allowed to adhere for 48 H in standard growth medium. The cells were
treated with recombinant FLAG tagged CTRP3, CTRP1, or vehicle the cells were then
incubated with rabbit anti-FLAG primary antibody followed by fluorochrome-conjugated
secondary antibody. Cells were then mounted with an anti-fade mounting medium with DAPI,
and immunofluorescence was visualized.
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Figure 4.2: CTRP3 Binds to Hepatocytes in Vitro. H4IIE hepatocytes were grown in standard
media and then treated for 1 H ± CTRP3-FLAG (5 µg/ml). The cells were then washed and
collected in PBS, fixed in 4% formaldehyde, and then incubated with rabbit anti-FLAG antibody
followed by fluorochrome-conjugated secondary antibody and analyzed for mean fluorescent
intensity (MFI) by flow cytometry. Representative image (20% of points shown) of raw flow data
from vehicle treated (A) or CTRP3-FLAG treated (B). C, the MFI ± CTRP3 normalized to
vehicle for each independent replicate. D, Percent of the cells that were positive for each
experiment. Data for figures C & D are from 3 independent replicates performed on different
days with separate lots of recombinant CTRP3-FLAG protein with each replicate performed in
triplicate and reported as mean ± SD. * P < vs. 0.0001 vehicle.

The next series of experiments examined the effects of CTRP3 on hepatocyte
oxygen consumption to determine if the binding of CTRP3 to the hepatocytes resulted in
a physiological effect. Pre-treatment with recombinant CTRP3 (5 μg/ml) had no effect
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on lipid oxidation in hepatocytes under standard conditions. However, in the presence of
an excess of free fatty acids (200 μM palmitate) there was 24% increase in total oxygen
consumption in the CTRP3 pre-treated cells, indicating greater FFA utilization (Figure
4.3).
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Figure 4.3: CTRP3 Increases Oxygen Consumption. Cells were pre-incubated with 5 µg/ml
recombinant CTRP3 or vehicle for 1 H before being placed into the XFe24 Extracellular Flux
Analyzer (Seahorse Bioscience) and oxygen consumption rate (OCR) was determined. OCR was
measured in the absence (A) or after the addition of 200 µM palmitate (B) added at 15 minutes
(vertical line). C, Area under the curve was calculated (mean OCR value at each interval*time)
for each treatment. Data represents the mean ± SD. Data is pooled from 3 independent
experiments each performed in triplicate, *P < 0.05 vs. vehicle + palmitate.

TriCEPS™-based ligand-receptor capture (LRC-TriCEPS)
An experiment with CTRP3-FLAG protein as a ligand and insulin as a control
ligand was performed on the H4IIE rat hepatoma cell line. Control experiments to
assess the technical quality were performed in parallel. Briefly, flow cytometry showed
successful oxidation and crosslinking of CTRP3-TriCEPS and Insulin-Triceps to the cell
surface glycans (Figure 4.4A). LC-MS/MS analysis showed a total enrichment of
glycopeptides of 11% (261 peptides). Under these conditions, INSR (insulin receptor)
could be identified and quantified in the control dataset. From these experiments 5
putative receptors for CTRP3 were identified with two reaching statistical significance:
Lysosomal-associated membrane protein 1 (LAMP-1) and Lysosome membrane protein
2 (LIMP II) (Table 4.1 and Figure 4.4B) As LAMP1 was the promising candidate further
experiments were carried out focusing on LAMP1.
Table 4.1: Table 8TriCEPS™-Based Ligand-Receptor Capture (LRC-TriCEPS)
TriCEPS™-Based Ligand-Receptor Capture (LRC-TriCEPS)

Uniprot
identifier
P14562
P27615
P16391
D3ZQ57
Q66HD0

Protein
LAMP1
LIMPII
HA12
D3ZQ57
ENPL

Number
peptides
4
2
3
2
2
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of log2FC adj.pvalue
1.00
1.06
0.53
0.50
1.13

5.79E-05
0.035
0.046
0.046
0.072

Figure 4.4: H4IIE Rat Hepatoma Cells Were Treated With TriCEPs Conjugated to Insulin or
CTRP3. A, The binding of ligands to cell surface receptors was detected by Steptavidin FITC
(The TriCEPS™ reagent contains biotin) and analyzed for mean fluorescent intensity (MFI).
Representative image (20% of points shown) of raw flow data from vehicle treated. B, The
samples were analyzed by Mass spectrometry (Dualsystems Biotech, AG) and the adjusted pvalue (ANOVA, adjusted for multiple comparisons) for the differential abundance of each protein
was plotted against the magnitude of the fold enrichment between insulin and CTRP3 samples.
Proteins are considered significant if fold change >2 and P<0.05. Two proteins (LAMP1 and
LIMPII) were statistically significant.

LAMP1 antibody prevents CTRP3 binding
To follow up the LRC-TriCEPS experiment we repeated the FACS experiments
with the addition of a polyclonal antibody to LAMP1 in an attempt to disrupt the binding
of CTRP3. The co-incubation of H4IIE cells with recombinant CTRP3 and anti-LAMP1
polyclonal antibody was found to significantly attenuate the binding of CTRP3 to H4IIE
cells (Figure 4.5E and F).
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Figure 4.5: Blocking LAMP1 Suppresses CTRP3 Binding. H4IIE hepatocytes were grown to
confluence in standard media and then treated for overnight ± CTRP3-FLAG (2.5 µg/well) and ±
polyclonal LAMP1 antibody (10 µg/well, to block potential CTRP3 binding sites). The cells were
then washed and collected in PBS, fixed in 4% formaldehyde, and then incubated with rabbit
anti-FLAG antibody followed by fluorochrome-conjugated secondary antibody and analyzed for
mean fluorescent intensity (MFI) by flow cytometry. A-D, Representative flow data from H4IIE
hepatocytes. A MFI >100 was taken as positive and is indicated in the flow plots with a gray bar.
A, pooled cells with no primary antibody (isotype or negative control). B, cell incubated with
vehicle, C, recombinant CTRP3-FLAG protein, or D, co-incubated with recombinant CTRP3FLAG protein plus poly-clonal anti-LAMP1. E, Percent of the cells that were positive from each
experiment. F, the MFI ± CTRP3 normalized to vehicle for each independent replicate. Data for
figures E & F are from 3 independent replicates performed on different days with separate lots
of recombinant CTRP3-FLAG protein with each independent replicate performed in triplicate
and reported as mean ± SD. * P < 0.001 vs. vehicle; ** P < 0.001 vs. CTRP3+LAMP1.
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CTRP3 Co-IP
We found that treatment with CTRP3 did not affect LAMP1 protein
concentration in total lysate (Figure 4.6C). To determine whether CTRP3 interacted with
LAMP1 protein a Co-IP assay was performed. Immunoblot analysis was able to
successfully identify LAMP1 in the CTRP3 Co-precipitate and not in the FLAG peptide
or buffer only treated cells, further supporting the hypothesis that CTRP3 and LAMP1
associate in vivo (Figure 4.6D).

Figure 4.6: Co-Immnunoprecipitation (Co-IP) and Immunoblot Analysis. H4IIE cells were
treated overnight with vehicle, FLAG peptide, or recombinant FLAG tagged CTRP3 (rCTRP3).
Total protein homogenate (A & C) or immunoprecipitate (B & D) were separated by SDS-page
gel and transferred to nitrocellulose membrane. A & B, after immunoblot total protein was
visualized by brief incubation with Ponceau S staining solution (5% acetic acid & 0.1% Ponceau
S). C, LAMP1 in total protein homogenate was similar between treatments. D, Co-IP results
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showing LAMP1 binds to CTRP3. Samples were immunoprecipated with anti-FLAG Affinity Gel
followed by immunoblotting with antibodies against LAMP1.

DISCUSSION
Summary of Findings
We successful showed using two different techniques that recombinant purified
mammalian-expressed CTRP3 protein binds to the H4IIE hepatoma cells. Further, using
real-time oxygen consumption data we demonstrate that pre-conditioning cells with
CTRP3 increased oxygen consumption rates. Because electrons produced by free fatty
acid (FFA) beta-oxidation enter the electron transport chain at the level of complex 2
while those derived from glucose enter at complex 1, a switch from glucose to FFA
utilization is accompanied by higher oxygen consumption rates (45, 46). Theoretically,
the switch from glucose to FFA should cause ~30% increase in OCR (46, 47), if ATP
turnover remains unchanged. The ~24% increase observed in oxygen consumption
supports previous findings that CTRP3 increases FFA oxidation in hepatocytes (29).
Lastly, the LRC-TriCEPS experiments successfully identified and quantified statistically
two proteins as targets for CTRP3: LAMP1 and LIMPII. Additionally, 3 other potential
candidates were identified, and although there were not statistically quantified they were
reported as putative receptors (Table 4.1). Follow-up experiments with an anti-LAMP1
polyclonal antibody partially attenuated the binding of CTRP3 to the cells and Co-IP
experiments further confirmed that LAMP1 associates with CTRP3.
Study Limitations
Although we were successfully able to identify potential proteins which act as
the receptor to mediate the effects of CTRP3 there are some study limitations that need
to be addressed. This study used an immortalized cell line as a model for hepatocytes.
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H4IIE cells were chosen because they are a commonly used liver cell culture line that
maintains characteristics of intact liver cells and we have shown previously that CTRP3
had a physiological response in these cells (i.e. reduced neutral lipid accumulation
(29)). Further, the LRC-TriCEPS protocol requires isolated cells and isolation of
hepatocytes from intact liver requires enzymatic dissociation which by definition disrupts
cell surface proteins. Future visualization and co-localization studies using intact liver
will need to be performed. Additionally, binding and lipid oxidation experiments with
primary hepatocytes also need to be performed. Lastly, the identification of putative
receptors that are not exclusively expressed in hepatocytes still leaves open the
possibility that the liver-specific in vivo effects of CTRP3 (29) are mediated through
indirect mechanisms and not necessarily through direct actions of CTRP3 on
hepatocytes.
Hepatic function of CTRP3
Previous work has shown that the novel adipokine CTRP3 has a potent
biological effect on the liver (9, 29). Briefly, both transgenic overexpression of CTRP3
and daily administration of recombinant CTRP3 reduced diet-induced hepatic
triglyceride accumulation (29). Further, acute injections of recombinant CTRP3
significantly lowered hepatic gluconeogenesis up to 8 H post injection (9). However, the
mechanism by which CTRP3 attenuates hepatic triglyceride levels or gluconeogenesis
is unknown. Due to the similarity of CTRP3 and other members of the CTRP family to
adiponectin it has been suggested that the actions of all members of the CTRP family
are mediated through the adiponectin receptors: T-cadherin, and adiponectin receptors
1 and 2 (35, 48). However, our previous work suggests that CTRP3 works through a
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novel mechanism, as unlike adiponectin, CTRP3 did not increase hepatic AMPK
phosphorylation (9, 29, 32). Moreover, we observed no effect of CTRP3 treatment in
skeletal muscle, which has all three of the known receptors for adiponectin (9, 33, 34).
Lastly, we have shown that CTRP3 but not CTRP1 binds to hepatocytes in vitro (Figure
4.2), which supports our hypothesis that CTRP3 is a distinctive member of the C1q/TNF
superfamily and functions through a unique receptor.
Functions of LAMP1 and LIMPII
LAMP1 [Uniprot identifier P14562 (Figure 4.7)] is also known as 120 kDa
lysosomal membrane glycoprotein (LGP-120) and CD107 antigen-like family member A
(CD107a). LAMP1 was initially characterized as a type 1 integral lysosomal membrane
glycoprotein that is found in a wide variety of tissues (including the liver) and is
commonly used as a lysosomal marker (49, 50). However more recently it has been
reported that LAMP1 also shuttles to the plasma membrane, indicating that it could act
as a cell surface receptor (51, 53). Further, ~5% of the total LAMP1 protein is located on
the plasma membrane due to lysosomal fusion (51, 54). The transient nature of LAMP1
plasma membrane associate could explain why, in a theoretically homologous cell
culture population, only about 15–20% of the cells appeared to be positive for CTRP3
binding (Figure 4.1 and 4.2). Regardless, we were able to show that pretreatment with
CTRP3 was sufficient to induce a significant increase in oxygen consumption. Although
LAMP1, in addition to LAMP2, account for ~50% of lysosomal membrane proteins (49)
the exact function for LAMP1 remains elusive, as LAMP1 knockout mice do not appear
to have any functional or structural abnormality (49, 52). Currently, it is believed that
LAMP1 is partly responsible for maintaining lysosomal integrity and function (49), and
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plasma membrane expression of LAMP1 may play a role in tumor cell differentiation
and metastasis (49). The potential role of LAMP1 in mediating hepatic lipid oxidation
has not been explored.
A

B

Figure 4.7: Protter Visualization of Identified Peptide. The identified peptides of LAMP1 (A) and
LIMP II (B) are visualized with Protter [62]. Identified peptide sequences are signified by blue
circles.
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Lysosome membrane protein 2 (LIMPII, Uniprot identifier P27615) is also
known as Scavenger receptor class B member 2 (SCRB2), 85 kDa lysosomal
membrane sialoglycoprotein (LGP85), and as CD36 antigen-like 2. LIMPII was first
discovered in a rat liver lysosomal fraction (55) and accounts for ~4% of all lysomal
proteins (56). Although the presence of LIMPII on the plasma membrane of hepatocytes
has not been examined, LIMPII has been shown to be essential in the cell-to-cell
adhesion of the plasma membrane of cardiac myocytes (intercalated discs) (57).
Although the exact function in metabolism for LIMPII is unknown the closely related
protein Scavenger receptor class B member 3 (SCARB3, also known asCD36/FAT) has
been implicated in hepatic insulin resistance (58, 59) and immunity (60), both functions
implicated with CTRP3. Like SCARB3, LIMPII has been shown to bind to the adhesive
glycoprotein thrombospondin-1 (56), which may help mediate cell-to-cell interactions.
LIMPII is primarily expressed in the liver, placenta, adrenal cortex and adrenal gland
(50) and has already been implicated as an internal receptor responsible for shuttling
the enzyme glucocerebrosidase to the lysosome. Glucocerebrosidase metabolizes the
sphingolipid glucocerebroside, and when deficient results in Gaucher disease (or the
excessive accumulation of the lipid molecule glucocerebroside in cells (i.e. hepatocytes)
(61).
Although lacking known cellular signaling functions, both LAMP1 and LIMPII are
expressed in hepatic cells, where they are potentially positioned to interact with CTRP3.
Further, both of these proteins can be found on the cell surface however, they may act
as a co-receptor for an as-yet-unidentified signaling receptor through which CTRP3
transmits metabolic signals.
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SUMMARY AND CONCLUSION
Previous work has shown that the novel adipokine CTRP3 has a potent
biological effect on the liver (9, 29). However, the mechanism by which CTRP3
attenuates hepatic triglyceride levels is unknown. The purpose of this study was to
determine if we could successfully use the relatively new methodological approach,
LRC-TriCEPS™ method, to identify potential receptors, which mediate the biological
effects of CTRP3. We have successfully identified two potential novel receptors using
the LRC-TriCEPS™ technique: LAMP1 and LIMPII. Although, the intracellular signaling
mechanism remains unknown the identification of the receptors for CTRP3 and other
members of this family is an important prerequisite of the development of small
molecule drug candidates that work through CTRP3 receptors to exert effects beneficial
to human health.
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CHAPTER 5
SUMMARY & FUTURE DIRECTIONS
HIF-1α
The studies described in the proceeding chapters provided insight into the
cellular mechanisms by which HIF-1α and CTRP3 mediate metabolic changes to
combat stress. HIF-1α remodels metabolism to confer ischemic cardioprotection. In the
present studies, enhanced glycolytic flux in HIF-1α hearts ex vivo was indicated by
significantly higher 13C-labeled lactic acid accumulation as ischemia progressed (0 to 30
mins). Additionally, phosphorylation of glycogen synthase was significantly upregulated
by HIF-1α. Because phosphorylation deactivates GS, this favors glycogenolysis in the
ischemic heart. These findings are consistent with our previous data that lactate
released into the perfusate was significantly elevated following ischemia of HIF-1α heart
at 30 mins (J. Wu et al. 2013). In spite of the increase of glycolytic flux, paradoxically,
we found that 13C-labeled glycogen (glucose reserves) levels were maintained at preischemic levels in HIF-1α hearts for up to 30 mins of ischemia, whereas glycogen levels
were depleted after 5 mins of ischemia in WT hearts. In addition, the rate of 13CGlucose incorporation into glycogen is maintained at pre-ischemic levels in HIF-1α
hearts for up to 30 mins of ischemia while becoming undetectable in WT hearts.
Combined these findings suggest that HIF-1α is responsible for an unexpected source
of glucose that contributes to the glucose:glycogen turnover during no-flow ischemia in
heart. Further, our experiments demonstrated that HIF-1α triggers myocardial
gluconeogenesis in response to ischemia. Specifically, we observed gluconeogenetic
intermediates [m+3] isotopologues such as glucose-6-phosphate, fructose-6-phosphate,
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and fructose 1,6-bisphosphate were only present in the HIF-1α ischemic hearts. The
only theoretical source of the [m+3] molecules is from catabolism of the U-13C6 glucose
(all six carbons are 13C-labeled) and the derived metabolites combining with
endogenous unlabeled glucose-derived metabolites (Consult Figure. 2.3).

Taken together, our data indicates that HIF-1α triggers active myocardial
gluconeogenesis to enhance glucose:glycogen turnover and subsequent ATP
production in response to ischemic stress. We surmise that the glycolytic ATP
production provides energy in a compartmentalized fashion for ionic sarcolemmal
function (i.e. Na+-K+ pump), thus promoting cellular ionic homeostasis. Without
maintaining cellular ionic homeostasis, the cell membrane integrity would quickly
degrade and the cell would die. Therefore, these studies identify a novel
cardioprotective mechanism for cardiomyocytes exposed to prolonged ischemic stress.
These results also suggest that the steps of gluconeogenesis that is induced by
HIF-1α, is the point where pyruvate is converted to OAA via pyruvate carboxylase (PC)
for anaplerotic carboxylation rather than at the pyruvate dehydrogenase (PDH) reaction.
This warrants further investigation.
We have previously described several metabolic pathways upregulated by HIF1α possibly contribute to the energetic supply for gluconeogenesis in this model. For
example, HIF-1α induces fumarate respiration allowing the cardiomyocyte to use
fumarate as a terminal electron acceptor instead of O2 to sustain anaerobic
mitochondrial polarization. In another alternative pathway leading to the synthesis of
major metabolic end product succinate under anaerobic conditions, GTP is produced
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from the conversion of α-ketoglutarate to succinate via substrate level phosphorylation
(Hochachka et al. 1975). Our data show higher GTP levels in HIF-1α hearts at 30 min of
ischemia, compared to WT.
Future Studies with HIF-1α
Taken together, we show that HIF-1α-induced gluconeogenesis in myocardia
could contribute to the ischemic cardioprotection. Work on the very large metabolomics
dataset will continued. Specific gluconeogenesis inhibitors exist. Future studies will
utilize these these inhibitors to establish that the maintenance of glycolysis and
glycogen reserves in HIF-1α hearts is dependent upon glyconeogenesis. Loss of
ischemic tolerance of the HIF-1α heart upon the blockade of gluconeogenesis would
establish the cardioprotective role of this pathway. In addition, the use of 13C labeled
glucogenic amino acids will be employed to probe the carbon backbone source of the
synthesized glucose in the HIF-1α hearts.
CTRP3
Although, we initially proposed that CTRP3 would also be cardioprotective, our
studies indicate that CTRP3 overexpression does not promote cardiofunctional
recovery and tissue viability in ischemic mouse heart. These data suggest that CTRP3
does not confer specific protective effect in myocardia, at least in this ex vivo model of
hypoxic injury. However, CTRP3 transgenic mice failed to develop high fat diet-induced
hepatic steatosis (Peterson et al. 2013). To pursue this further we investigated the
CTRP3 specific effects in the lipid-overloaded hepatocyte.
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As a polypeptide adipokine, after being released from adipocytes into blood,
CTRP3 must reach the liver and bind to a receptor in hepatocytes to exert its regulative
effects on hepatic lipid metabolism and inflammation. Our first set of experiments led to
the successful identification of putative CTRP3 receptors, LAMP-1 and LIMP II, which
may mediate hepatic metabolism. Further, we demonstrated that in the presence of
excess fatty acids CTRP3 significantly enhance fatty acid utilization by hepatocytes.
Thus, here CTRP3-induced fatty acids oxidation protects H4IIE hepatocytes against
potential metabolic stress from lipid accumulation.
Future Studies with CTRP3
The specific function of LAMP1 is unknown and LAMP1 knockout animals do
not present with an observable phenotype when fed standard chow diet (Andrejewski et
al. 1999). Experiments with high-fat feeding with LAMP1 knockout animals have not
been performed, and we propose that the loss of LAMP1 will ameliorate the hepatoprotective effect of CTRP3. Further, as LAMP1 is not exclusive to hepatocytes (LAMP1
is also found on macrophages) CTRP3 may act through blocking lipid-induced
inflammation on the macrophages and hepatocytes. Therefore, future studies should be
performed to identify whether CTRP3 binds directly to macrophages as well. Lastly, as
there is no known intracellular signaling pathway initiated by LAMP1 it could be that the
binding of CTRP3 to LAMP1 is essential for inhibiting the binding of ligand to a separate
receptor. In support of this CTRP3 has been shown to block lipopolysaccharides (LPS)
from activating the Toll-like receptor 4 in isolated macrophages, even though CTRP3
did not bind directly to either the Toll-like receptor 4 or LPS (Kopp et al. 2010). Future
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studies should be performed with macrophages and hepatocytes from LAMP1 knockout
animals to test this potential mechanism.
Conclusion
Both HIF-1α and CTRP3 regulate metabolism and offer tissue specific
protection to various stressors.
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